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Colorectal cancers (CRCs) are composed of an amalgam of cells with distinct 
genotypes and phenotypes. Here we reveal a previously unappreciated 
heterogeneity in the biosynthetic capacities of CRC cells. We discover that the 
majority of ribosomal DNA transcription and protein synthesis in CRCs occur in a 
limited subset of tumor cells that localize in defined niches. The rest of the tumor 
cells undergo an irreversible loss of their biosynthetic capacities as a consequence of 
differentiation. Cancer cells within the biosynthetic domains are characterized by 
elevated levels of the RNA Polymerase 1 subunit A - POLR1A. Genetic ablation of 
POLR1A-high cell population imposes an irreversible growth arrest to CRCs. We 
show that elevated biosynthesis defines stemness in both LGR5+ and LGR5- tumor 
cells. Therefore, a common architecture in CRC is a simple cell hierarchy based on 







Only subsets of tumor cells isolated from CRC samples, the so-called cancer stem 
cells (CSCs), display tumorigenic potential upon transplantation into recipient mice 
(Dalerba et al., 2007; Merlos-Suárez et al., 2011; O’Brien et al., 2007; Ricci-Vitiani et 
al., 2007; Vermeulen et al., 2010). This finding lead to the notion that CRCs are 
organized according to a stem cell hierarchy. Indeed, tumor cells present in full-
blown CRCs echo the phenotypes observed in healthy colonic mucosa, including 
stem cell-like and differentiated-like states characterized by expression programs 
reminiscent of those present in their normal counterparts (Dalerba et al., 2011; 
Merlos-Suárez et al., 2011; Vermeulen et al., 2008). Lineage-tracing experiments in 
xenografts demonstrated that LGR5+ stem cell-like tumor cells exhibit long-term self-
renewal and differentiation capacities whereas KRT20+ differentiated cells produce 
mostly short-lived progeny (Cortina et al., 2017; Shimokawa et al., 2017). However, 
genetic ablation of LGR5+ cells in these cancer models triggers a regenerative 
response by which LGR5-negative tumor cells convert to an LGR5+ state and 
regenerate the CSC pool (Shimokawa et al., 2017; de Sousa e Melo et al., 2017). In 
addition, de Sauvage and colleagues showed that ablation of LGR5+ cells does not 
impair primary CRC growth yet these cells are necessary for the expansion of 
metastases (de Sousa e Melo et al., 2017). These studies raise a number of 
important caveats. In particular, CSCs have been recognized by expression of stem 
cell marker gene LGR5 yet many CRCs contain few or no LGR5+ cells (Merlos-
Suárez et al., 2011; Shimokawa et al., 2017). It is unclear whether these LGR5-
negative CRCs still rely on a CSC hierarchy or not. One possibility is that CSCs may 
not be simply defined by LGR5 expression in some CRCs or even that particular 
tumors may contain LGR5+ and LGR5-negative CSC subsets. Furthermore, although 
evidence supporting tumor cell plasticity is well established, it remains unknown 
whether all cell types present in CRCs are equally capable of regenerating the CSCs 
pool. We reasoned that understanding the functions that characterize CSCs beyond 
expression of marker genes might help address these important issues. 
 
While characterizing the properties of CSCs, we found that most rRNA and proteins 
synthesized in CRCs are contributed by a limited subset of cells that reside 
immediately adjacent to the stroma. In contrast, as tumor cells undergo 
differentiation, they experience an irreversible loss of rRNA and protein synthesis 
capacity. By exploring these unexpected findings, we demonstrate that zonation 
patterns of rDNA transcription and protein synthesis in CRC reflect the existence of a 
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Zonation of rRNA and protein synthesis in CRC 
We discovered striking zonation patterns of protein and ribosomal RNA (rRNA) 
synthesis in CRCs. O-propargyl-puromycin (OP-P) is a puromycin analog that is 
incorporated into nascent polypeptides (Blanco et al., 2016; Liu et al., 2012; Signer et 
al., 2014). In CRC patient-derived xenografts (PDX), the OP-P+ domain was 
visualized as strings of cells adjacent to the stroma that surrounds each tumor gland 
(Figure 1A). Closer inspection confirmed that OP-P incorporation was largely 
restricted to tumor cells occupying basal positions, with the highest protein synthesis 
rates corresponding to those cells in closest proximity to the underlying mesenchyme 
whereas cells that reside outside these domains, including KRT20+ differentiated 
tumor cells, did not incorporate OP-P (Figure 1A’ and A’’). Stromal cells stained 
strongly for OP-P. These OP-P zonation patterns were present in all xenografts 
analyzed that included subcutaneous, orthotopic and metastatic CRC models 
(Examples in Figure 1B, 1C, S1A, and S1B). We also measured rDNA transcription 
by inoculating mice with 5-Ethynyl Uridine (EU), a ribonucleotide analog that can be 
visualized using click chemistry (Jao and Salic, 2008). EU incorporates mainly into 
rRNA (Jao and Salic, 2008) and, similar to OP-P, it labeled preferentially the nucleoli 
of tumor cells located adjacent to tumor stroma after a 2 h pulse (Figure 1D, 1D’ and 
1D’’, S1C and S1D). 
 
We next searched for surface marker genes that overlapped with CRC biosynthetic 
zones identified above. In CRCs, highest EPHB2 levels are expressed by a subset of 
undifferentiated tumor cells that reside in proximity to the stroma (Batlle et al., 2002; 
Merlos-Suárez et al., 2011). EPHB2-high cells resided within OP-P+ tumor domains 
(Figure S1E and S1F). Flow cytometry of dissociated xenografts demonstrated that 
EU and OP-P incorporation was largely restricted to EPHB2-high tumor cells and 
further confirmed that most EPHB2-low tumor cells exhibited near-zero rDNA 
transcription and protein synthesis rates (Figure 1E and 1F). We obtained similar 
measurements in three xenografts from tumors with distinct genotypes (Figure 1G). 
We also performed transcriptional profiling of tumor cells purified from fresh surgical 
CRC specimens according to EPHB2 surface levels (n=10) (Figure 1H). This study 
confirmed significant enrichment in gene sets associated to rRNA and protein 
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synthesis in EPHB2-high compared to -low tumor cells in all samples (Figure 1I and 
Table S6). Overall, these findings imply the existence of well-defined biosynthetic 
domains in CRC dedicated to producing rRNA and proteins (Figure 1J). This 
organization occurs independently of the site of growth and it is a defining feature of 
many CRCs.  
 
Characterization of biosynthetic cells in CRC 
Recent reports revealed that CRCs expand through the proliferation of tumor cells 
that are located at the tumor edges in contact with the stroma that surrounds 
xenografts (van der Heijden et al., 2019; Lenos et al., 2018). In our model systems, 
however, there were no significant differences in the numbers of Ki67+ cells located 
at the tumor center and in the periphery (Figure S2A, S2B, S2C and S2D). We 
confirmed this finding in CRC patient samples (Figure S2E and S2F). The OP-P+ 
and EU+ domains only encompassed a fraction of the Ki67+ tumor cell population 
and were similarly distributed in the tumor center and the periphery (Figure 2A and 
2B). 
 
Previous studies have shown that a substantial proportion of CRCs exhibited few or 
no LGR5+ cells (Figure 2C and 2D) (Merlos-Suárez et al., 2011; Shimokawa et al., 
2017). For convenience, we reproduce in Figure 2E the results from Merlos-Suárez 
et al. We investigated how the expression of LGR5 correlated with rRNA and protein 
synthesis zonation patterns described above. To this end, we knocked-in a tdTomato 
cassette in the LGR5 locus of patient-derived organoids (PDOs) using a 
CRISPR/Cas9-based approach that we described elsewhere (Cortina et al., 2017) 
(Figure 2F). In these experiments, we used two different PDOs as model systems: 
PDO-p18 carries inactivating mutations in APC and functional inactivation of P53 
(van de Wetering et al., 2015) and contains a large proportion of LGR5+ cells. PDO7 
is mutant in four main driver pathways (APC, KRAS, ATM, SMAD4) and represents a 
model for CRCs with a discrete LGR5+ cell population (Table S4). Subsequently, we 
generated xenografts inoculating these LGR5 reporter PDOs in immunodeficient 
mice. tdTomato-high cells purified from dissociated xenografts upregulated ISC-
specific genes such as LGR5 and SMOC2 whereas tdTomato-negative cells 
expressed markers of intestinal differentiation (Figure 2G and 2J). PDO-p18-derived 
xenografts contained abundant LGR5+ cells (Figure 2H) and we observed overlap 
between the LGR5+ and OP-P+ domains in these tumors (Figure 2I). In contrast, 
PDO7 xenografts exhibited a smaller proportion of LGR5+ cells scattered through 
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tumor glands (Figure 2K), most of which were distributed within the OP-P-
low/negative domain (Figure 2L).  
 
It was also evident that tumor glands formed by differentiated KRT20+ tumor cells did 
not incorporate OP-P or EU, even if these differentiated cells were immediately 
adjacent to stroma (examples in Figure 1A-D and 2M). The lumens of these KRT20+ 
glands often contained dead cells (Figure 2N and 2N’) suggesting that differentiated 
CRC cells exhibit short lifespans as previously proposed (Shimokawa et al., 2017). In 
addition, most CRCs analyzed included a small proportion of KRT20+ (0.5% - 2%) 
scattered within the OP-P+ domain (Figure 2O, 2O’ and 2O’’). We conclude that the 
EU+ and OP-P+ domains of CRCs are always positioned adjacent to the stroma yet 
the stromal localization per se neither directly defines the biosynthetic capacities of 
CRC cells, nor the expression of stem cell, differentiation or proliferation marker 
genes.  
 
Shutdown of rRNA and protein synthesis rates during tumor cell differentiation 
Tumor cell differentiation can be enforced in CRC cell lines and organoids through 
the inhibition of WNT signaling (van de Wetering et al., 2002). Expression of a 
tamoxifen-inducible dominant negative TCF4 transcription factor in LS174T or 
SW403 CRC cells triggered the expression of KRT20 and other differentiation 
markers coinciding with a decline in the levels of ISC genes (Figure 3A). Likewise, 
mouse intestinal tumoroids engineered to bear activating mutations in Kras (G12D) 
combined with loss of function alleles of p53 and a doxycycline-regulated shRNA 
targeting Apc (AKP tumoroids) (Dow et al., 2015) undergo differentiation upon 
removal of doxycycline leading to shutdown of beta-catenin/TCF4 transcription 
(Figure 3B). We observed that after prolonged WNT blockade and differentiation (7 
days), CRC cell lines and mouse tumoroids exhibited a significant reduction in EU 
and OP-P incorporation (Figure 3C-3D, S3A and S3B). The uptake of methionine 
analog L-homopropargylglycine (HPG) was also largely reduced (Figure 3E and 3F 
and below). In addition, prolonged WNT blockade caused a drop in pre-rRNA levels 
(Figure 3G). 
 
The Y10B antibody recognizes mainly cytoplasmic 5.8S rRNA loaded in ribosomes 
(Lerner et al., 1981; Witte et al., 1991). Using this antibody, we found that loss of OP-
P and EU incorporation coincided with a decrease in the number of assembled 
ribosomes (Figure 3H). Y10B staining of primary formalin fixed-paraffin embedded 
(FFPE) patient samples (n=24) revealed extensive intratumoral heterogeneity in 
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ribosome density. Elevated expression of the pan-differentiation marker KRT20 
correlated strongly with lack of 5.8S staining in the vast majority of patients (Example 
in Figure 3I-3J, and S3C-S3D). Hence, KRT20+ CRC cells not only display a 
pronounced reduction in rRNA synthesis and protein synthesis rates but also exhibit 
a reduced number of ribosomes.   
 
To track production of proteins during cell differentiation, we made use of HPG, 
which is incorporated into proteins without disturbing their functions (Calve et al., 
2016; Dieterich et al., 2010; Signer et al., 2014). CRC cell lines expressed KRT20 
protein 4 days after blockade of the WNT pathway (Figure 3L). At this early time 
point, many KRT20+ cells incorporated HPG implying that during the onset of 
differentiation protein synthesis rates remain elevated. Yet, we observed a 
progressive decline in HPG incorporation during the following 3 days that coincided 
with downregulation of rRNA and protein synthesis machinery (Figure 3K and 3L). 
Pulse-chase experiments revealed that the majority of KRT20 was synthesized 
during the first three days after WNT blockade yet only limited amounts were 
produced at a later time point (Figure 3M-3P). Therefore, fully differentiated tumor 
cells retain long-lived proteins that were synthesized before the protein synthesis 
machinery was shut down. 
 
Biosynthetic CRC cells express elevated POLR1A levels  
We noticed that prolonged WNT blockade in in vitro CRC models caused 
downregulation of mRNAs encoding for subunits of RNA Polymerase-I holocomplex 
including POLR1A, POLR1B and POLR1C (Figure 4A and 4B). The rDNA specific 
transcription factors TIF-1A and UBTF were also downregulated (Figure 4B). We 
confirmed substantial reduction of the major subunit of the RNA Polymerase 1 
complex - POLR1A - after 7 days of WNT blockade by western-blot (Figure 4C) and 
by immunofluorescence (Fig 4D and S4A). Consistently, KRT20+ cells present in 
xenografts displayed relatively low POLR1A levels (Figure S4B and S4C). The 
expression of POLR1A was increased in CRC samples compared to normal mucosa, 
which is consistent with augmented rDNA transcription in tumors (Figure S4D). 
To study POLR1A in vivo, we used CRISPR/Cas9 technology to knock-in an EGFP 
cassette in frame with the start codon of POLR1A gene (Figure 4E). The EGFP-
POLR1A fusion protein was located in the nucleolus of knock-in organoids (Figure 4F 
and S4E). Upon inoculation into immune-deficient mice, PDOs generated xenografts 
displaying extensive EGFP-POLR1A heterogeneity. EGFP-POLR1A and KRT20+ 
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areas were located in mutually exclusive domains in PDXs (Figure 4G and S4F). 
Isolation of the EGFP-POLR1A-high cell population (brightest 10% tumor cells) from 
dissociated tumors followed by western blot confirmed elevated POLR1A levels 
whereas their negative counterparts expressed KRT20 (Figure 4H, 4I, S4G and 
S4H). EU and OP-P were almost exclusively incorporated in EGFP-POLR1A-high 
cells purified from both PDO7 and PDO-p18 xenografts (Figure 4J-4N and S4I). 
Therefore, elevated POLR1A levels characterize the cells that reside within the 
biosynthetic domains of CRC.   
 
EGFP-POLR1A-high cells purified from xenografts exhibited higher organoid forming 
capacity than EGFP-POLR1A-low cells (Figure S4J). Importantly, experiments of 
tumor cell isolation followed by transplantation into secondary recipients revealed 
that the EGFP-POLR1A-high cell population present in both PDO-p18 and PDO7 
was largely enriched in tumor-initiating cells (Figure 4O). Intrasplenic inoculation of 
tumor cell populations also demonstrated that the vast majority of metastasis 
initiating cells reside within the tdTomato-POLR1A-high cell fraction (Figure S4K and 
S4L).  
 
Characterization of tumor cell heterogeneity by single-cell profiling 
We next studied the relationship between stem and differentiated gene programs and 
the POLR1A-high cell population by single-cell RNA sequencing (scRNA-seq) of 
PDO7- and PDO-p18-derived xenografts. Unsupervised clustering identified discrete 
tumor cell populations that we subsequently ascribed to either ISC-like or 
differentiated-like (absorptive, enteroendocrine and mucosecreting) phenotypes 
(Figure 5A, 5F, S5A and S5B). The LGR5 expression signature labeled ISC-like cells 
whereas KRT20 was upregulated in differentiated-like tumor cells (Figure 5B, 5G, 
S5A and S5B). These analyses also identified a distinctive population of 
undifferentiated cells that expressed elevated POLR1A-high signature levels in both 
xenografts (Figure 5C and 5H). The transcriptomes of the POLR1A-high cell 
population in both PDO-P18 and PDO7 xenografts were enriched in gene sets 
related to proliferation and biosynthetic pathways (Table S7). Crucially, the two PDO 
xenografts differed in the expression patterns of the LGR5 signature. Many tumor 
cells in PDO-p18, including a large fraction of POLR1A-high cell population, were 
ISC-like and expressed LGR5 (Figure 5B and 5C). In contrast, there was a limited 
overlap between the POLR1A-high and the LGR5+ cell populations in PDO7 (Figure 
5G and 5H). Using PDO7 bearing LGR5-tdTomato and POLR1A-EGFP reporter 
cassettes (Figure S4M) we corroborated that only a minority (10%) of POLR1A-
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EGFP-high cells were LGR5-tdTomato+ cells (Figure S4N). Within the POLR1A-high 
population, LGR5+ and LGR5- cells exhibited differential expression of metabolism-
related gene sets (Figure S4O and S4P).  
 
Finally, analysis of gene expression dynamics using pseudotime reconstruction 
predicted that the origin of the trajectory in both PDO7 and PDO-p18 xenografts 
corresponded to the POLR1A-high cells whereas differentiated-like cells were 
positioned at endpoints (Figure 5D, 5E, 5I and 5J). Remarkably, changes in cell 
states over the pseudotime path were characterized by a progressive decline of 
POLR1A-high signature expression levels (Figure S5C-F).  
 
Clonal analysis of POLR1A+, LGR5+ and KRT20+ cells 
By means of CRISPR/Cas9, we knock-in lineage tracing cassettes into endogenous 
POLR1A, LGR5 or KRT20 locus of PDO7 (Figure 5K). We titrated the amount of 
tamoxifen necessary to recombine approximately the same number of cells (1-2%) in 
the three creERT2 PDO-derived xenografts (Figure S5G). This low recombination 
frequency facilitated the analysis the three cell types at the clonal level (Figure 5P). 
We found no significant differences in the fraction of non-necrotic tumor cells 
between the three experimental conditions (Figure S5H). The number of clones 
generated by POLR1A+ cells was sustained over time whereas the frequency LGR5-
derived clones declined at late time points (Figure 5L). In addition, POLR1A+ tumor 
cells produced larger clones (Figure 5M, 5N and 5P) and contributed substantially 
more cells than LGR5+ cells (Figure 5O). Our data also indicates that both POLR1A 
and LGR5 populations generated progeny that underwent differentiation as shown by 
KRT20 labeling (Figure 5Q). Based on these observations, we tentatively conclude 
that POLR1A+ biosynthetic cells represent the main population fueling the growth of 
PDO7 tumors.  
 
Most KRT20+ differentiated cells exhibited low proliferative potential and were short-
lived (Figure 5L, 5M and 5O). Yet, a small proportion of KRT20+ cells (2-5%) 
generated progeny that expanded over time (Figure 5N), which may indicate that 
either some cells retained proliferative potential or that a restricted subset of 
differentiated cells recovered stem cell potential thorough plasticity. It is, however, 
important to consider that at the earliest time point of tamoxifen treatment (3 days), 
only a minority (15%) of the tdTomato marked cells represented mature differentiated 
cells as shown by lack of expression of KRT20 protein (Figure S5I and S5J). We 
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speculate that due to the drop of protein synthesis rates, the probability of inducing 
recombination in terminally differentiated cells is low.  
 
POLR1A-high cells are necessary for tumor growth 
We next performed experiments of cell ablation using PDOs that carry an inducible 
caspase 9 (iCasp9) knocked-in in either the POLR1A or the LGR5 locus (Shimokawa 
et al., 2017) (Figure 6A, 6B, 6J and 6N). Xenografts derived from inoculation of 
knock-in PDOs in mice exhibited heterogeneous POLR1A-tdTomato-iCasp9 
(POLiCT) levels, including KRT20+ cells that express very low levels of the reporter 
(Figure 6C and 6D). Indeed, analysis of tdTomato by flow cytometry confirmed a 
wide range of expression, with bright and dim cells differing more than 25-fold in 
reporter levels (Figure 6E). POLR1A-tdTomato-high cells expressed higher levels of 
POLR1A (Figure S6A) and exhibited increased OP-P and EU incorporation 
compared to POLR1A-tdTomato-low cells (Figure S6C and S6D). Induction of 
iCasp9 dimerization with AP20187 (Shimokawa et al., 2017) selectively eliminated 
the brightest POLR1A-tdTomato cells after 5 days (Figure 6E). In addition, we 
observed an increased frequency of cells expressing low reporter levels suggesting 
tumor cell differentiation. By immunofluorescence, we confirmed that only tumor cells 
expressing the highest Tomato levels were ablated in these experiments (Figure 
S6B). Upon treatment, the epithelial compartment, but not the stromal cells of these 
xenografts lacked OP-P and EU incorporation (Figure 6G, S6D) demonstrating that 
we effectively eliminated the cell population that synthesized proteins and rRNA in 
tumors. Ablation of POLR1A-high cells completely halted the growth of both PDO-
p18 and PDO7 xenografts (Figure 6F). It also caused an increase in the number of 
differentiated cells shown by KRT20 and Alcian blue staining, although this effect 
was more prominent in PDO7 than in PDO-p18 (Figure 6H, 6I, S6E and S6F). 
Genetic ablation of LGR5 cells (Figure 6K, 6O, S6G and S6H) using an equivalent 
approach was effective, but only halted growth and OP-P incorporation in PDO-p18 
xenografts (Figure 6L and 6M).  PDO7 tumors grew steadily and the zonation pattern 
of protein synthesis was not altered despite lack of LGR5+ cells (Figure 6P and 6Q). 
Overall, these results imply that biosynthetic cells labeled by high POLR1A levels 
sustain tumor growth in both CRCs. The broad expression of LGR5 in PDO-p18, 
which expands into the POLR1A+ compartment, makes this tumor susceptible to 
LGR5+ cell ablation. In contrast, only a minority of LGR5+ cells in PDO7 express 
POLR1A and exhibit biosynthetic capacities and, therefore, the bulk of the LGR5+ 




Therapeutic targeting of biosynthetic tumor cells 
Treatment of xenografts with FOLFIRI, a chemotherapeutic commonly used in CRC 
patients, slowed down tumor growth and reduced the number of POLR1A-tdTomato-
high cells (Figure S6I, S6J and S6K). Incorporation of OP-P+ was also diminished 
(Figure S6L). Concomitantly, FOLFIRI-treated xenografts exhibited an increased 
abundance of POLR1A-tdTomato-Low cells (Figure S6K) and contained substantially 
more KRT20+ cells at experimental endpoints (Figure S6L and S6M). Therefore, 
FOLFIRI treatment reproduces to some extent the effects of genetic ablation of 
POLR1A-high cells although it failed to completely eliminate the tumor biosynthetic 
compartments.  
 
BMH-21 is a small molecule that induces degradation of POLR1A (Peltonen et al., 
2014). In vitro treatment with BMH21 downregulated POLR1A levels and induced 
overt differentiation of PDO7 (Figure S6N, S6O and S6P). We observed similar yet 
milder effects in xenografts (S6Q and S6R). Higher BMH21 doses resulted in mouse 
toxicity, which limited its therapeutic efficacy in the in vivo setting.  
 
Irreversible phenotype of KRT20+ CRC cells 
Experiments of POLR1A-high cell ablation during 10 days followed by a long 
recovery period in the absence of dimerizer revealed that growth remained 
continuously halted (Figure 7A and 7B). Analysis of the remaining tumor mass 7 
days after stopping dimerizer treatment showed the presence of KRT20+ tumor cells 
in direct contact with the stroma that exhibited largely reduced protein synthesis rates 
(Figure 7C). After extended periods of time (>25-30 days), tumors slowly reinitiated 
growth, which was likely due to residual cells that acquired resistance to iCasp9 
ablation as inferred by the fact that tumors continuously treated with dimerizer 
expanded with almost identical kinetics (Data not shown) and that organoids 
established from samples taken at the onset of re-growth phase were resistant to 
dimerizer treatment in vitro (Figure S7A and S7B).  
 
To explore further the irreversibility of the differentiated state, we made use of AKP 
tumoroids bearing a doxycycline-regulated shApc cassette (Figure 7D). Tumoroids 
forced to differentiate in vitro during 2 days in the absence of doxycycline (APC ON) 
that were subsequently cultured for 7 days with doxycycline (APC OFF), partially 
retained rRNA transcription, protein synthesis and growth rates (Figure 7E-7G). 
Therefore, loss of biosynthetic capacity due to short-term differentiation (2d) is 
reversible to some extent. In contrast, switching to doxycycline media after 5 days of 
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differentiation did not restore growth (Figure 7G and S7D), despite re-expression of 
the GFP-Apc shRNA cassette (Figure S7C). Most cells in these tumoroids were 
KRT20+ (Figure 7H) and exhibited reduced capacity to synthesize rRNA or proteins 
even after prolonged culturing in doxycycline-supplemented media (i.e. 7 days) 
(Figure 7E and 7F). Consistent with this finding, AKP tumoroids did not recover 
POLR1A levels after long-term (7d) differentiation (Figure 7H and 7I). Transcriptomic 
profiling of mouse tumoroids at early (2 days of Apc restoration) versus late stage 
differentiation (7 days of Apc restoration) revealed that downregulation of genesets 
related to biosynthesis such as ribosome, nucleolus, ribonucleoprotein assembly, 
ribosome biogenesis, etc., occurred only 7 days after restoring APC, concordantly 
with the time frame of irreversible differentiation (Figure S7F and S7G).  
 
To study reversibility in vivo, we generated xenografts by inoculation of AKP 
tumoroids in mice (Figure 7J). Removal of doxycycline halted tumor growth, 
upregulated expression of KRT20 and reduced EU and HPG incorporation in 
xenografts (Figure 7K, 7L and S7E). This phenomenon was partially reversible by 
doxycycline supplementation after 8 days, including restoration of HPG and EU 
incorporation. Yet, 20 days after continuous APC expression, the addition of 
doxycycline did not rescue tumor growth, rRNA or protein syntheses rates (Figure 
7K, 7L and S7E). The remaining tumor mass was composed mostly of KRT20+ cells 
directly in contact with the tumor stroma. POLR1A levels remained downregulated at 
this later time point (Figure 7M). Therefore, prolonged differentiation causes 






Homeostasis of adult tissues requires controlled protein synthesis rates and distinct 
cell types in healthy tissues, including stem cells and their differentiated progeny, 
exhibit different biosynthetic capabilities (Blanco et al., 2016; Signer et al., 2014). In 
tumors, this regulation is disrupted by oncogenic alterations, many of which enhance 
the cell biosynthetic machinery, including rDNA transcription, ribosomal biogenesis, 
and protein production rates (Bustelo and Dosil, 2018; Pelletier et al., 2017; Ruggero, 
2012). Genetic manipulations leading to diminished ribosomal function and protein 
production exert robust anti-tumorigenic effects (Ajore et al., 2017; Barna et al., 
2008; Peltonen et al., 2014; Signer et al., 2014). Notwithstanding the high 
biosynthetic requirements of cancers, our data evidence a progressive loss of 
biosynthetic activity due to the pervasive differentiation that tumor cells experience in 
CRCs. Fittingly, in models of WNT-depend pancreatic cancer, inhibition of WNT 
signaling using Porcupine inhibitors causes differentiation (Jiang et al., 2013), and 
this process is accompanied by downregulation of POLR1A, POLR1B and other 
genes involved in ribosomal biogenesis (Madan et al., 2018). It is well established 
that signaling pathways that promote biosynthesis such as mTOR enhance cap-
dependent translation, whereas stress conditions, including nutrient deprivation or 
hypoxia can activate alternative modes of translation, e.g., via internal ribosome 
entry sites (Robichaud and Sonenberg, 2017; Robichaud et al., 2019). Thus, the 
vastly reduced protein synthesis rates present in terminally differentiated cells may 
still be sufficient to translate specific mRNAs. Likewise, high protein synthesis rates 
shown by POLR1A-high cells may favor the translation of RNA subsets important for 
the biology of cancer stem cells.  
 
Many CRCs contain abundant LGR5+ cells, yet lineage tracing analysis suggests 
that only a small proportion of them function as CSCs (Kozar et al., 2013). Our 
results support this conclusion. Other CRCs contain few to no LGR5+ cells (Merlos-
Suárez et al., 2011; Shimokawa et al., 2017) but may still exhibit a hierarchical 
organization. The same caveats could be possibly applied to other putative stem cell 
marker genes. In addition, LGR5- cells present in primary CRCs act as seeds for 
metastasis in experimental models (Fumagalli et al., 2020). Our study defines 
functionally the CSC population in CRC: we propose that CSCs represent a subset of 
tumor cells with elevated rDNA transcription rates and protein synthesis capacity 
dedicated to fuel tumor growth. We show that both LGR5+ and LGR5- tumor cells 
that display elevated biosynthetic features function as CSCs in transplantation 
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experiments and also in intact tumors. The finding that the biosynthetic cell 
population occupies a basal position within the tumor glands suggests a role for the 
underlying mesenchymal cells in instructing their phenotype. However, proximity to 
this niche does not define unequivocally an elevated biosynthetic capacity as many 
CRCs contain KRT20+ and LGR5+ cells in direct contact with the stroma that 
nevertheless exhibit low protein and rRNA synthesis rates. Our findings fit well with a 
model whereby the properties of cancer cells are defined both by the 
microenvironment as well as by cell-intrinsic programs dictated by a stem cell 
hierarchy. 
 
Previous experiments of KRT20+ tumor cell fate mapping have shown that this cell 
population gives rise mostly to short-lived progeny but can revert to an LGR5+ state 
upon ablation of this CSC pool (Shimokawa et al., 2017). It is however important to 
consider that at the onset of differentiation CRC cells incorporate elevated OP-P and 
EU levels. We speculate that these early differentiated cells exhibit a plastic 
phenotype and can return to a CSC state if necessary. Nevertheless, our findings 
imply that as differentiation progresses, the capacity of differentiated cells to revert 
their state becomes gradually limited due to the downregulation of the rDNA 
transcription machinery. In a subset of CRCs, continuous ablation of biosynthetic 
CSCs exhausts the progenitor cell pool and causes irreversible tumor cell 
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FIGURE TITLES AND LEGENDS 
 
Figure 1. rDNA Transcription and Protein Synthesis across Different Models of 
CRC. (A) OP-P incorporation in a patient-derived xenograft (PDX). Lu: Lumen; Str: 
Stroma. Scale bars: in (A): 500 µm; in (A’): 100 µm; in (A”): 250 µm. Dashed lines 
outline epithelial glands. (B) OP-P incorporation in primary human CRC implanted 
orthotopically in mice. Str: Stroma. Scale bars: in (B): 2.5 mm; in (B’): 100 µm; in (B”): 
250 µm. Dashed lines outline epithelial glands. (C) OP-P incorporation in 
spontaneous liver metastasis generated from intrasplenic (IS) injection of PDO7. Lu: 
Lumen. Scale bars: in (C): 5 mm; in (C’) and (C”): 250 µm. (D) EU incorporation in a 
PDX. Dashed lines outline epithelial glands. Lu: Lumen. Scale bars: in (D): 500 µm; 
in (D’): 250 µm; in (D”): 50 µm. Images in (A), (B), (C) and (D) are tiled and stitched. 
(E) Analysis of OP-P and EU in EPHB2 tumor cell populations. (F) Representative 
flow cytometry plots of EU and OP-P into EPHB2 positive or negative tumor cells 
purified from indicated PDXs. (G) % of OP-P and EU positive cells within EPHB2 
high and low tumor cells. ****p=1.92x10-7, ****p=1.51x10-9 in a mixed effects linear 
model (n=3 PDX, 2 mice for each PDX). (H) EPHB2-based cell purification from 
human CRC samples. (I) GSEA of EPHB2 high and low tumor cells sorted from 
primary CRCs. For all GOSLIM terms FDR q-val=0. (J) Spatial zonation model of 
protein synthesis/rDNA transcription in CRCs.  
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Figure 2. Characterization of Biosynthetic Tumor Cells in CRC 
(A and B) Representative Ki67 and OP-P (A) or EU (B) patterns in PDXs. Dashed 
lines outline epithelial glands. Scale bars: in (A): 100 µm; in (B): 250 µm. (C and D) 
In situ hybridization of Lgr5 and immunohistochemistry (IHC) of KRT20 in serial 
sections of two representative human primary CRCs. Scale bars: 100 µm. (E) 
Quantification of Lgr5+, KRT20+ and double negative cells across a collection of 
primary CRC human samples (reproduced from Merlos-Suarez et al., 2011). (F) 
Schematic representation of the Lgr5-inducible Caspase9-tdTomato (LiCT) targeting 
construct. (G and J) RT-qPCR analysis of ISC and differentiation genes in PDO-p18-
LiCT (G) and PDO7-LiCT (J). Bars depict the mean and upper/lower limits of relative 
expression obtained from representative experiment. (H and K) LGR5-tdTomato 
staining in tumor xenografts. Scale bars: in (H): 2.5 mm; in (K): 1 mm. (I and L) 
LGR5-tdTomato and OP-P staining in xenografts. Scale bars: in (I): 50 µm and in (L): 
100 µm. (M, N, and O) OP-P and KRT20 staining in PDO7 xenografts. In (M) dashed 
line delimits a KRT20 positive gland in contact with the stroma. (N) and (N’) show 
KRT20+ cells in the lumen of a tumor gland.  (O) Single KRT20+ cells intermingled 
within the OP-P positive domain (arrows). Str: stroma; Lu: Lumen. Scale bars: in (M): 
250 µm; in (N): 500 µm; in (O): 100 µm. Images in (A), (B),(I),(L),(M),(N) and (O) are 
tiled and stitched. 
 
Figure 3. WNT-Driven Differentiation Causes Protein and RNA Synthesis 
Decrease. (A) qRT-PCR analysis of ISC and differentiation genes in control (Wnt 
ON) or differentiated (Wnt OFF) LS174T CRC cells. (B) qRT-PCR analysis of ISC 
and differentiation genes in control (APC OFF) or differentiated (APC ON) AKP 
mouse organoids. Bars depict the mean and upper/lower limits of relative expression 
obtained from a representative experiment. (C) OP-P incorporation and KRT20 in 
LS174T CRC cells over differentiation. Scale bars: 50 µm. (D) % of OP-P and EU 
positive cells detected by flow cytometry in LS174T after 7 days of in vitro 
differentiation. For OP-P ****p<0.0001 (n=4); for EU **p=0.0078 (n=3) in an unpaired 
two-tailed t-test. Confidence intervals (CI) are mean±SEM. (E) HPG incorporation 
and KRT20 staining in AKP mouse organoids over differentiation. Scale bars: 50 µm. 
(F) % of HPG and EU positive cells detected by flow cytometry in AKP organoids 
over differentiation. For HPG ****p=<0.0001 (n=4); for EU *p=0.0131 (n=3) in an 
unpaired two-tailed t-test. CI are mean±SEM. (G) pre-rRNA levels in LS174T and 
SW403 cells after 4 days of differentiation. Bars depict the mean and upper/lower 
limits of relative expression obtained from a representative experiment. (H) 5.8S 
rRNA and KRT20 staining in LS174T cells over differentiation. Scale bars: 20µm. (I) 
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Representative 5.8S and KRT20 staining of a primary human CRC sample. Scale 
bar: 1mm. (J) Representative plot of KRT20/5.8S intensity analysis from (I).	KS-test 
p=8.35x10-5. (K) Experimental set-up for (L). (L) HPG incorporation and KRT20 
staining in LS174T cells during differentiation. Arrows pointing at double positive cells 
on day 4. Scale bars 20 µm. Images are tiled and stitched. (M) Experimental design 
for protein tracing experiment. (N) Immunoprecipitation of KRT20 using whole protein 
extracts from HPG-labeled and traced samples. Numbers below the panels indicate 
intensity of the signal. (O and P) Quantification of KRT20 and HPG intensity at day 3 
(O) and at day 7 (P) of differentiation. 
 
Figure 4. POLR1A High Tumor Cells Display high Biosynthetic and 
Tumorigenic capacities. (A) CRC cell line differentiation via inducible NTCF4. (B) 
RT-qPCR of rRNA transcriptional machinery components in LS174T after 4 days of 
in vitro differentiation. Bars depict the mean and upper/lower limits of relative 
expression obtained from representative experiment. (C) Western blot analysis of 
POLR1A and KRT20 in LS174T during differentiation. (D) POLR1A staining in 
LS174T tumor cells after 7 days of in vitro differentiation. Scale bars: 20 µm. Right 
panel: quantification of nuclear area occupied by POLR1A in control (Wnt ON) or 
upon differentiation (Wnt OFF). p=0.0005 in unpaired two-tailed t-test (n=4 images 
for Wnt ON and n=3 images for Wnt OFF). CI are mean±SEM. (E) Knock-in construct 
for the generation of EGFP-POLR1A fusion protein. (F) EGFP-POLR1A labels the 
nucleoli of PDO-p18 in vitro. Scale bar: 50 µm. (G) EGFP-POLR1A and KRT20 
staining in PDO-p18 xenografts. Scale bars: 50 µm, and 10 µm in insets. (H) 
Representative flow cytometry plot of EGFP-POLR1A in knock-in PDO-p18 
xenografts (right plot). Squares indicate the sorted EGFP-POLR1A populations. Top 
10% was considered to be POLR1A high. (I) Western blot of POLR1A and KRT20 in 
indicated sorted populations from (H). (J) Representative flow cytometry plot of EU 
incorporation in EGFP-POLR1A cells purified from PDO-p18 xenografts. (K) % of EU 
positive cells in POLR1A sorted cells from tumor xenografts. ****p<0.0001 in a mixed 
effects linear model (n=2 different PDX and 2 experimental replicates). (L) 
Representative flow cytometry plot of OP-P incorporation in EGFP-POLR1A tumor 
cells populations purified from PDO-p18 xenograft. (M) % of OP-P positive cells in 
POLR1A sorted cells from tumor xenografts. ***p=0.001 in a mixed effects linear 
model (n=2 different PDX, 3 replicates for PDO-p18 and 1 for PDO7). (N) OP-P and 
POLR1A (left panel) and KRT20 and POLR1A (right panel) staining in PDO-p18 
xenograft. Scale bar: 50 µm. (O) Tumor initiation capacity of EGFP-POLR1A high 
and low tumor cells purified from PDO-p18 (left) and PDO7 (right). Kaplan-Meier 
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plots (n=8 xenografts). **p=0.0032 for PDO-p18 and ****p<0.0001 for PDO7 in a 
Gehan-Breslow-Wilcoxon test. 
 
Figure 5. Mapping of Tumor Cell Populations by Single Cell profiling and clonal 
analysis. (A and F) T-SNE plots of 388 (PDO-p18, (A)) and 511 (PDO7, (F)) single-
cells from tumor xenografts colored by cluster identities. (B, C, G and H) Normalized 
expression of the LGR5 and of the POLR1A high signatures in PDO-p18 (B and C) 
and PDO7 (G and H). (D, E, I and J) Trajectory graph representations for PDO-p18 
and PDO7, color-coded by pseudo-time ordering of cells (D and I) and their cluster 
identity (E and J).  (K) Knock-in constructs and experimental design for lineage 
tracing experiments. (L) Quantification of total number of clones per tumor area at 
indicated time points. Each dot represents quantifications in a section of a different 
tumor. n=4-10 tumors per time point and cell population.*p=0.0107, **p<0.002 in a 
two-way ANOVA using Turkey’s multiple comparison test. CI are mean±SEM. (M) 
Quantification of number of large clones (>15 cells) per tumor area at indicated time 
points. Each dot represents quantifications in a section of a different tumor. n=4-10 
tumors per time point and population. ****p<0.0001 in a two-way ANOVA using 
Turkey’s multiple comparison test. CI are mean±SEM. (N) Quantification of clone 
size over time. Data represents the average number of cells per clone. Each dot 
represents quantifications in a section of a different tumor. n=4-10 tumors per time 
point and population. *p=0.026 and ***p=0.005 in a one-way ANOVA using Turkey’s 
multiple comparison test for the last time points. CI are mean±SEM. (O) 
Quantification of the total number of tomato positive cells per tumor sample over 
time. Data represents the average of tomato positive cells per time point. Each dot 
represents quantifications in a section of a different tumor. n=4-10 tumors per time 
point and population. *p=0.035 and ***p=0.007 in a one-way ANOVA using Turkey’s 
multiple comparison test for the last time points. CI are mean±SEM. (P) 
Representative images of tdTomato on tumor xenografts. Arrowheads point to single 
cell clones induced at day 3. Scale bars: 50 µm in d3, 100 µm in d15 and d23/30. (Q) 
IF for KRT20 and tdTomato in tumor sections after 23d or 30d of tamoxifen 
treatment.  White arrowheads indicate tdTomato clones containing KRT20+ cells. 
Scale bars: 50 µm. Images in (Q) are tiled and stitched. 
 
Figure 6. POLR1A-High Tumor Cells sustain CRC Growth.  
(A) POLR1A knock-in cell ablation cassette (POLiCT) in PDOs. (B) Experimental 
design of in vivo ablation experiments. (C and D) Representative images of tdTomato 
and KRT20 in xenografts from POLiCT knock-in PDOs. Scale bars:  250 µm. (E) 
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Representative flow cytometry plots of tdTomato expression in controls or 4 days-
post POLR1A ablation in PDO7 (left) and PDO-p18 (right) in vivo. WT unmodified 
clones are shown for reference. (F) Tumor growth during chronic POLR1A ablation. 
****p<0.0001, ***p=0.004 in a two-tailed t-test. For PDO7: n=3 control and n=6 
treated tumors. For PDO-p18 n=5 control and n=6 treated tumors.  CI are 
mean±SEM. (G) OP-P incorporation in control tumors or after 10 days of POLR1A 
ablation. Str: stroma. Dashed lines delimit tumor glands from stroma. Scale bars: 250 
µm and 100 µm. (H) KRT20 staining in control or POLR1A-ablated PDO7. Scale 
bars: 2.5 mm. (I) Quantification of KRT20 positive areas in control or POLR1A 
ablated PDO7 tumors. ***p= 0.0009 in an unpaired two-tailed t-test. (n=8 controls 
and n=9 treated tumors). CI are mean±SEM. (J) Knock-in ablation cassette for the 
generation of LGR5-iCaspase9-tdTomato (LiCT). (K) Representative flow cytometry 
plot of LGR5-tdTomato levels in control or after 5 days of dimerizer in PDO-p18. (L) 
Tumor growth during chronic ablation of LGR5+ tumor cells in PDO-p18. ***p=0.0010 
(M) OP-P patterns in untreated mice or after 14 days of dimerizer. Dashed lines 
delimit the tumor glands. Scale bars: 250 µm. Str: stroma. (N) Knock-in ablation 
cassette for the generation of LGR5-iCaspase9-EGFP (LiCG) in PDO7. (O) 
Representative flow cytometry plot of LGR5-EGFP in control conditions or after 5 
days of dimerzer in PDO7. (P) Tumor growth during chronic ablation of LGR5 tumor 
cells in PDO7. (Q) OP-P patterns in untreated mice or after 14 days of dimerizer. 
Scale bars: 250 µm. Images in (C) and (D) are tiled and stitched. 
 
Figure 7. Loss of Biosynthetic Capacity drives CRC into an Irreversible 
Differentiation State. (A) Experimental design.  (B) Tumor growth in untreated, 
during permanent dimerizer treatment (in red), or after 10 days of dimerizer treatment 
(in yellow) to ablate POLR1A in PDO7. ***p=0.0010 ***p=0.0008 in an unpaired two-
tailed t-test (n=3 control, n=6 always dimerizer, n=6 stop dimerizer tumors). CI are 
mean±SEM. (C) OP-P incorporation and KRT20 expression in control tumors or in 
tumors 7 days after dimerizer withdrawal. Scale bars: 1mm (upper images) and 2.5 
mm (lower images). (D) Experimental design for in vitro reversibility experiments in 
AKP organoids. Arrows indicate sample collection (E and F) Quantification of EU (E) 
or (F) HPG incorporation during differentiation (ON) and after reversion (ON/OFF). 
For EU: p=0.6, p=0.5, **p=0.004, **p=0.0019 (n=4, 3, 2, 3, 3) and HPG: p=0.62, 
**p=0.007, ****p<0.0001, **p=0.0015 (n=4, 4, 2, 4, 2) in an unpaired two-tailed t-test. 
CI are mean±SEM. (G) Organoid formation assay during in vitro differentiation (ON) 
and after reversion (ON/OFF). p=0.10, *p=0.01, p=0.06 (n=4, 4, 4, 2) in an unpaired 
two-tailed t-test. CI are mean±SEM. (H) Representative examples of POLR1A and 
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KRT20 staining in organoids during in vitro differentiation (ON) or after reversion 
(ON/OFF). Scale bars: 50 µm. (I) Quantification of POLR1A nuclear area from (H). 
p=0.6, *p=0.01, ***p=0.0001, ***p=0.0006 (n=6, 4, 3, 5 images per condition) in an 
unpaired two-tailed t-test. CI are mean±SEM. (J) Experimental design for in vivo 
reversibility experiments of AKP tumors. (K) Tumor growth corresponding to (J). 
**p=0.0088, p=0.709 in an unpaired two-tailed t-test (n=8, 10, 7 tumors). CI are 
mean±SEM. (L) Representative images of HPG incorporation and KRT20 in AKP 
tumor xenografts. (M) POLR1A and KRT20 in AKP xenografts during differentiation 
(ON) and after the reversion (ON/OFF). Scale bars: 50 µm (N) Differentiation-driven 







Further information and requests for resources and reagents should be directed to 




Knock-in CRC organoids and NTCF4 expressing CRC cell lines generated in this 
study are available from the Lead Contact with a completed Materials Transfer 
Agreement. 
 
Data and code availability 
Expression arrays and RNA-seq data are available at GEO with accession number: 
GSE125232. scRNA-seq data is available at GEO with accession number: 
GSE148345. Computer code is available upon request.  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Mouse strains and tumor cell injections 
All experiments with mouse models were approved by the Animal Care and Use 
Committee of Barcelona Science Park (CEEA-PCB) and the Catalan government. To 
generate subcutaneous xenografts from PDOs we inoculated 150.000 (PDO7), 
50.000 (PDO p19b) or 1.5 million cells (PDO-p18) in a format of 4-5 days grown 
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undissociated organoids into Beige (CB17.Cg-PrkdcscidLystbg-J/Crl) or NSG 
(NOD.Cg-Prkdc<scid>Il2rg<tm1Wjl>/SzJ) female mice in 100 µl of 50% BME2-HBSS 
(Cultrex). For mouse-derived AKP xenografts, 5000 cells in 100µl of 50% matrigel-
HBSS (Corning) were injected into the flanks of Swiss nude (Crl:NU(Ico)-
Fox1nu) female mice. Cell number was determined by trypsinizing and counting an 
aliquot of a total cellular suspension. Tumor volume was measured with manual 
calipers and calculated according to the formula (length x width x height)/2. To 
generate liver metastasis dissociated organoids (single cells) were injected 
intrasplenically (IS) in NSG mice as described in (Calon et al., 2012; Tauriello et al., 
2018). Cells were counted and resuspended in HBSS for injection using 0.5 x 106 
cells in 70uL per mouse. For tumor initiation assays, viable single cells from 
disaggregated xenografts were sorted according to their EGFP-POLR1A levels and 
transplanted subcutaneously into Beige/NSG recipient mice in 100uL of 50% BME2-
HBSS. For metastasis initiation experiments, viable single cells from disaggregated 
xenografts were FACS sorted according to their POLR1A-tdTomato levels and 
transplanted intrasplenically in NSG mice in 70ul of HBSS.    
 
In vivo treatments 
For the inducible ablation experiments, we treated animals with 5mg/kg of dimerizer 
(AP20187, Medchem express, HY-13992) when tumors reached an average size of 
40-50 mm3. For acute treatments (5-10 days) animals were treated daily and for 
chronic treatments (>10 days) every 2-3 days. Control animals were treated with 
vehicle for the same period of time. For in vivo reversibility experiments, mice 
bearing subcutaneous AKP xenografts were given 2 mg/ml DOX in drinking water 
until the tumors reached the size of about 50mm3. After that, DOX was removed for 
the indicated periods (8 days ON or 20 days APC-ON) before the mice were given 
DOX again (APC-OFF). To induce Cre-mediated recombination of the tdTomato 
cassette for the linage tracing experiments, mice bearing subcutaneous tumor 
xenografts (50-70mm3) receive a single intraperitoneal tamoxifen (Sigma) injection of 
1mg/kg for KRT20 and 10mg/kg for POLR1A or two consecutive intraperitoneal 
tamoxifen injections of 250mg/kg for LGR5. For the experiments with the small 
molecule RNA polymerase I inhibitor, BMH21 (Invivochem), we injected 
intraperitoneally a daily dose of 100 mg/Kg over the period of 10 days once the 
tumors have reached an average size of 50 mm3. Control animals were treated with 
vehicle over the same period. For chemotherapy experiments subcutaneous tumor 
xenorgrafts were generated by inoculating POLI-iCT PDO7 or PDO-p18 knock-in 
organoids. Once the tumors reach an average size of 70mm3 animals were treated 
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with three intraperitoneal injections of folfiri (100ul/20gr) at day 0, 3 and 7. Folfiri 
cocktail contained 5-FU (30mg/kg), Irinotecan (24mg/kg)) and Leucovorin (90mg/kg). 
Control animals were treated with vehicle following the same regimen. Animals were 
sacrificed the last day of the treatment and tumors were removed and processed for 
FACS and histological analysis. In all experiments animals were sacrificed at 
indicated time points or just before tumor size reached the volume permitted by 
Animal Facility regulations. In all animal treatments, individuals were randomized. 
 
Orthotopic models and primary CRC samples 
Patient-derived orthotopic xenografts (PDOX1 and PDOX2) were generated from 
fresh biopsies taken of peritoneal implants at tumor relapse after FOLFOX 
chemotherapy treatment from Hospital Universitari de Bellvitge (L’Hospitalet de 
Llobregat) and Hospital Moisès Broggi (Sant Joan Despi) from Barcelona.  
Orthotopic implantation procedure of colorectal human tumors was performed as 
described previously (Aytes et al., 2012). At the time of sacrifice mice implanted with 
PDOX2 tumor presented a synchronic hepatic metastasis that was isolated and 
implanted orthotopically into the liver of other four animals (PDOX2-MH). All patients 
gave written consent to participate in the study, and The Ethics Committee of the 
hospitals approved the study protocol. Animals were kept under pathogen-free 
conditions, and all animal work was conducted according to the guidelines from the 
Animal Care Committee at the Generalitat de Catalunya (Procedure 9111) in the 
Animal Core Facility of IDIBELL (AAALAC Unit 1155). The study was approved by 
the IDIBELL Ethical Committee and performed in accordance with guidelines stated 
in The International Guiding Principles for Biomedical Research involving Animals, 
developed by the Council for International Organizations of Medical Sciences 
(CIOMS). For the purification of EPHB2 tumor cell populations, fresh surgically 
resected Human CRC samples (n=10) were obtained from individuals treated at 
Hospital Clínic (Barcelona). Tumors were disaggregated following the protocol 
detailed in (Calon et al., 2012) and EPHB2 populations were purified as described in 
(Merlos-Suárez et al., 2011). For the 5.8S and KRT20 analysis, formalin-fixed, 
paraffin-embedded tissue blocks of primary human colorectal adenocarcinomas 
(n=24) were retrieved from the biobank of the Servei de Patologia from Hospital del 
Mar (Barcelona). Samples were obtained under informed consent and approval of 
the Tumor Bank Committees according to Spanish ethical regulations. The study 
followed the guidelines of the Declaration of Helsinki, and patient identity for 




Organoid in vitro culture 
Patient-derived organoids (PDOs) were cultured as described in (Cortina et al., 2017; 
van de Wetering et al., 2015). PDO7, was obtained from Prof. Stassi laboratory 
(Lombardo et al., 2011), PDO-p18 and PDO-p19b from Prof. Clevers laboratory 
(van de Wetering et al., 2015) and  AKP (shAPC-KP) organoids were a kind gift from  
Dr. Luke Dow’s laboratory. AKP organoids were embedded in Matrigel (Corning) and 
grown in Advanced DMEM/F12 supplemented with 10 mM HEPES, 2 mM GlutaMAX, 
B27, recombinant Noggin (100 ng/ml), EGF (50 ng/ml, Preprotech), and in the 
presence of Doxycycline (DOX, 2 µg/mL), (APC OFF) or absence (APC ON) to 
induce differentiation (Dow et al., 2015) at indicated time points. PDOs were 
embedded in a mixture of 70% BME2 and 30% Advanced DMEM/F12 with HEPES 
and GlutaMAX. PDO-p18 and PDO-p19b were cultured as is described by the 
Clevers laboratory (van de Wetering et al., 2015) and PDO7 as described in (Cortina 
et al., 2017). 
 
N-TCF4 expressing CRC cells lines  
LS174T and SW403 CRC cell lines obtained from ATCC were engineered to express 
a tamoxifen-inducible dominant negative form of TCF4 which consists in the β-
catenin-binding domain of TCF4 fused to a modified hormone-binding domain of the 
estrogen receptor (nTCF-ERT2)(van de Wetering et al., 2002). CRC cell lines 
expressing the nTCF-ERT2 construct were cultured under standard conditions 
(DMEM with 10% FBS) (Wnt ON) and when indicated, were treated with 1 µM 4-
hydroxytamoxifen (Merck H7904) (Wnt OFF). In all experiments, we only used the 
modified cell lines, and for simplicity we refer to them as LS174T and SW403 




Organoid formation experiments  
To run organoid formation experiments we used single cells obtained either by 
trypsinization from an in vitro experiment, or by FACS sorting from subcutaneous 
tumor xenografts. For the AKP organoid formation experiments, AKP organoids 
embedded in Matrigel were grown in the presence of DOX (APC OFF) or without 
DOX (APC ON) for the indicated periods (2 days ON, 5 days ON). Then, organoids 
were disaggregated to a single cell suspension using TrypLE reagent (Gibco), and 
seeded in 25 L Matrigel drops containing 1000 cells/drop, and DOX was added to 
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the medium in all conditions indicated with /OFF. To assess POLR1A organoid 
formation capacity, we disaggregated xenografts as described below and living cells 
were selected for EPCAM expression and sorted according to their endogenous 
POLR1A levels by FACS. Afterward, single cells were seeded in vitro in 25 µl BME2 
drops containing 1000 cells/drop per condition. To test the effect of BMH21 in vitro, 
single cells obtained by trypsinization from in vitro culture were seeded in 25 µl 
BME2 drops containing 1000 cells/drop per condition and were treated daily with 
BMH-21 (1µM). Control plates were treated with a vehicle and the growth was 
measured using the below described method.  In all cases, plates were scanned 
using ScanR inverted microscope (Olympus) at day 1 post-seeding to quantify the 
exact number of cells seeded per drop and at the experimental endpoint (day 7 post-
seeding). Full drops were scanned taking overlapping pictures at 4x magnification 
and at 8 different z-stacks with a separation of 200 µm. Z-stacks of all images were 
projected into a single image and the full drop was digitally reconstructed by stitching 
the different image projections using an Image J (Schindelin et al., 2009) custom-
made macro developed for this purpose. Total number and mean size of cells (i.e. 
any object with a diameter larger than 5 µm) or organoids (diameter larger than 400 
µm) were counted. Differences were assessed with Student’s t-test. 
 
Immunostaining and confocal imaging 
CRC cell lines grown on ethanol-sterilized glass coverslips were washed three times 
with PBS and incubated with 4% paraformaldehyde (PFA) for 15 min at room 
temperature, washed again with PBS and incubated for additional 5 min with 50 mM 
NH4Cl to quench PFA’s auto-fluorescence. Blocking and permeabilization were 
performed simultaneously for 1 h at room temperature in PBS containing 3% BSA 
and 0.3% Triton X-100. Coverslips were first incubated in a humid chamber overnight 
at 4ºC with the primary antibody diluted in the blocking/permeabilization solution. 
After extensive washing, the incubation with the secondary antibody was done for 1 h 
in the dark. In the case of the co-staining, both primary and secondary antibodies 
were mixed and used at the same time. Coverslips were mounted with DAPI-
Fluoromount-G (SouthernBiotech. 0100-20). For live imaging, PDOs were seeded in 
10 µl drops of BME2 in 8-well chamber coverslip (IBIDI) and covered with 200uL of 
the corresponding culture medium. 4-5 days grown organoids were directly incubated 
30 min at 37ºC with Hoechst 33342 1:1000 (Molecular Probes, R37605) prior to 
confocal visualization. For immunostainings, PDOs were seeded in microscopy 
chamber slides in thin layers of BME2 (20 µL per chamber). Samples were then fixed 
with 4% PFA for 15 min and quenched with 20 mM glycine for 20 min. 
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Permeabilization was achieved with 0.5% Triton X-100 for 30 min at room 
temperature, then a second blocking step with 1% BSA for 1 h at room temperature 
was performed. Samples were incubated with primary antibodies overnight at 4ºC in 
a dark chamber followed by the incubation with the correspondent secondary 
antibody for 1 h at room temperature in the dark. Washes were performed in 
between each step with PBS. Coverslips were mounted with DAPI-Fluoromount-G. 
To visualize OP-P (Medchem Source LLP, JA-1024), EU (Click Chemistry Tools, 
1261-100), and HPG (Click Chemistry Tools, 1067-100), slides were incubated with 
Click-it cocktail kit (Thermo Fisher) for 30 min in dark prior to antibody staining. 
Primary and secondary antibodies used for in vitro immunostaining were the same as 
the ones described for IF in paraffin sections. For paraffin-included organoid pellets, 
Matrigel drops were washed twice with PBS, incubated with formalin for 2h at RT, 
washed again with PBS, and left ON in formalin. The next day, two more washes 
with PBS were performed, and drops were put into a microcassette (Leica). 
Microcassettes were put into a regular histological cassette before paraffin 
embedding. Immunostainings were performed as is described in histology and tissue 
staining section. Images were taken with a Zeiss LSM780 confocal microscope. 
Whole organoid z-stacks were taken with a LEICA SP5 microscope. Next, images 
were background-substracted and maximum intensity projections were rendered by 
Imaris software version 9.1. 
 
Histology and tissue stainings 
Immunostainings were performed on 4 µm sections following a standard protocol. 
For PAS/Alcian Blue staining, samples were deparaffinated and rehydrated, followed 
by 5 min incubation with Alcian Blue solution pH 2.5 (1 g of Alcian Blue (Panreac), 97 
ml miliQ water, 100 ml glacial acetic acid) and dehydrated with ethanol 96%. 
Samples were rehydrated again, washed with distilled water, incubated with 1% 
periodic acid for 20 min, washed with tap water, incubated for 20 min with Schiff’s 
reagent (Sigma), washed with distilled water, and counterstained with hematoxylin 
prior to dehydrating and mounting with DPX (Panreac, 255254.1608). For 
immunohistochemistry (IHC), antigen retrieval was carried out by boiling in Tris-
EDTA buffer for 20 min, then samples were blocked with Peroxidase-Blocking 
Solution (Dako: S202386) followed by blocking with normal goat serum 10% 
(Jackson Immunoresearch, 005-000-121) in wash buffer 1X and incubated with 
primary antibody against TdTomato (rabbit, Rockland, 600-401-379) 1:200 in 
Envision FLEX antibody diluent (Agilent, K8006) at 4ºC overnight. Secondary 
antibody  BrightVision poly-HRP anti- Rabbit (Immunologic, DPVR-110HRP) was 
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added for 30 min at room temperature. Slides were counterstained with hematoxylin 
prior to dehydrating and mounting with DPX (Panreac, 255254.1608). Washes were 
performed in between steps with wash buffer 1X (Dako, K800721). To visualize OP-
P, EU, and HPG, slides were incubated with Click-it cocktail kit (Thermo Fisher, 100 
µl per slide) for 30 min in dark prior antibody staining. For immunofluorescence the 
applied protocol was the same as for IHC but blocking with normal donkey serum 
10% (Jackson Immunoresearch, 017-000-121) in wash buffer 1X with the following 
primary antibodies diluted in Envision FLEX antibody diluent (Agilent, K8006): 1:50 
EPHB2 (goat, R&D systems, AF467), 1:50 EPCAM-Trop1 (goat, R&D, AF960), 1:100 
KI67 (mouse, BD, 550609), 1:50 5.8S (mouse, Thermo Fisher, MA1-13017), 1:100 
POLR1A (mouse, Santa Cruz, sc-48385), 1:200 tdTomato or RFP (goat, Sicgen, 
AB8181-200), 1:200 EGFP (rabbit, abcam, ab183734), 1:50 KRT20 (mouse, Dako, 
M7019), and secondary antibodies: donkey anti-goat conjugated to Alexa-
488/568/647 (Life Technologies A11055, A11057, A21447), donkey anti-rabbit 
conjugated to Alexa-488/568/647 (Life Technologies A21206, A10042, A31573) and 
donkey anti-mouse conjugated to Alexa-488/568/647 (Life Technologies A-21202, 
A10037, A31571) at 1:400 for 1h art RT. DAPI was added at 1:2500 after secondary 
antibody incubation and slides were mounted with Fluorescent mounting medium 
(Dako, 53023). For in situ hybridization paraffin sections of human tissues were de-
waxed and hydrated following standard procedures. Samples were then treated with 
0.2N HCl for 15min at room temperature, washed 3X in PBS and incubated for 20min 
at 37ºC in Proteinase K (30 µg/ml in PBS). 0,2% glycine in PBS was added for 3 
minutes to neutralize Proteinase K activity and samples were then washed 2X in 
PBS. Sections were postfixed in 4% PFA for 10 min and washed 3X in PBS. Histone 
acetylation was performed by incubating the samples 2X 5 min in an H2O solution 
containing 1.5% triethanolamine, 0.15% HCl and 0.6% Acetic anhydride. Samples 
were then washed and prehybridized for 1h at 70ºC in prehybridization solution (50% 
Formamide, 5X SSC, 2% Blocking Reagent (Roche), 0.05% CHAPS, 5mM EDTA, 
50µg/ml Heparin and 50µg/ml yeast RNA). For Lgr5 ISH, mRNA probe was diluted 
500ng/ml in prehybridization solution and incubated for 48h at 65ºC.. Post-
hybridization washes were performed 3X 20 min in 50% Formamide / 2XSSC at 
65ºC. Sections were then rinsed in TBST buffer (0.1M Tris-HCl pH7.5, 0.15M NaCl, 
0.1% Tween20) and blocked for 30 min at room temperature in Blocking buffer (0.5% 
Blocking Reagent, 10% sheep serum in TBST). Sheep anti-DIG antibody (Roche) 
was diluted 1/5000 in blocking buffer and incubated overnight at 4ºC. Finally, 
samples were washed in TBST and then in NTM buffer (0.1M Tris pH9.5, 0.1M NaCl, 




Histological Image Acquisition  
Digital scanned brightfield and fluorescent images were acquired with a 
NanoZoomer-2.0 HT C9600 scanner (Hamamatsu, Photonics, France) equipped with 
a 20X objective and using NDP.scan2.5 software U10074-03 (Hamamatsu, 
Photonics, France). Fluorescent images were acquired with a mercury lamp unit 
L11600-05 couple to the NanoZoomer. All images were visualized with the NDP.view 
2 U123888-01 software (Hamamatsu, Photonics, France) with a gamma correction 
set at 1.8 in the image control panel. In each batch of samples, the same exposure 
time and gain per antibody have been used. All images were visualized with a 
gamma correction set at 1.0 and the sharpen filter enabled in the image controls 
panel of the NDP.view 2 U12388-01 software.  
 
sgRNA design  
Small guide RNAs were designed <15bp around de intended site of knock-in 
insertion using the http:// crispr.mit.edu web tool and were cloned into a pX330-IRFP 
hSpCas9 plasmid (Cortina et al., 2017) as described in http://www.genome-
engineering.org/crispr/wp-content/uploads/2014/05/CRISPR-Reagent-Description-
Rev20140509.pdf. The sgRNA sequences are available in Table S1.  
 
Donor plasmid construction 
750bp (LGR5, KRT20, POLR1A and AAVS1 constructs) of 5’ and 3’ homology arm 
(HA) flanking the knock-in insertion cassettes were amplified from PDO7 gDNA or 
synthetized by gene synthesis (Thermo Fisher) and cloned into pShuttle or pDONOR 
vectors. Homology arms EGFP-linker, LF2A-CreERT2-BGHpA, Lox-tagBFP-3xpA-
Lox-tdTomato-BGHpA insertion cassettes were generated by gene synthesis 
(Thermo Fisher) and cloned in the 5’HA-3’HA previously engineered pShuttle or 
pDONOR vectors (as described in Cortina et al., 2017).  
For the LGR5-iCaspase9-T2A-tdTomato donor (pDONOR-LGR5-iCT), a previous 
described p-shuttle-LGR5-LF2A-CreERT2 plasmid (Cortina et al., 2017) was 
modified by replacing the existing LGR5 5’ homology arm with a LGR5 5’ homology 
arm containing a STOP codon using PacI and SalI. Subsequently, the plasmid was 
digested with SgrDI/ and NotI-HF to substitute the LF2A-CreERT2 cassette with an 
IRES-iCasp9-T2A-TdTom-WPRE cassette, amplified by PCR from a plasmid 
obtained from T.Sato’s laboratory (Shimokawa et al., 2017).  For the LGR5-
iCaspase9-T2A-EGFP version TdTomato was then replaced by EGFP by digesting 
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with KflI and MluI, and introducing in-frame an iCasp9 fragment-T2A-EGFP, 
amplified by PCR from a custom gene synthesis DNA string (Thermo Fisher). 
For POLR1A-iCaspase9-T2A-tdTomato, the human POLR1A 5’ homology arm was 
cloned in the place of the LGR5 5’ homology arm in pDONOR-LGR5-iCT donor 
vector by PacI and SgrDI digestion. The 3’ homology arm was cloned by NotI-HF and 
AscI digestion. Inserts were amplified by PCR from custom gene synthesis DNA 
strings (Thermo Fisher). 
 
Generation of CRISPR-Cas9 knock-in PDOs 
PDOs were cultured and CRISPR-Cas9 knock-in as described in (Cortina et al., 
2017). In brief, to obtain PDOs expressing endogenous EGFP-POLR1A fusion 
protein we designed a sgRNA targeting a sequence flanking the TSS (or transcription 
start site) of the POLR1A locus. For the lineage tracing and the inducible caspase9 
knock-in generation, sgRNA sequences were designed to bind the 3’UTR.   After 
nucleofection with guide-Cas9 and donor plasmids (Cortina et al., 2017), single cell 
clones were derived and PCR screened for correct integration. Southern blotting was 
performed to assess off-target integrations. For each knock-in construct, we 
evaluated that the fluorescent cassette reported the expression of the gene of 
interest by RT-qPCR in vitro and in vivo in a similar manner as performed in Cortina 
et al., 2017.  
 
Genotyping PCR and Southern blot 
Single-cell derived clones were lysed in of 10 mM Tris, 1 mM EDTA, 1 % Tween 20 
and 0.4 mg/ml proteinase K lysis buffer for 1h at 55°C, and the enzyme was 
inactivated for 10’ at 95ºC. 2 µL of the lysate was directly used in the specific 
integration PCR. For the 5’ specific integration PCR, a forward primer binding gDNA 
upstream of the 5’ homology arm and a reverse primer at the beginning of the 
inserted cassette were used. Similarly, for the 3’ specific integration PCR a forward 
primer at the end of the inserted cassette and a reverse primer downstream of the 3’ 
homology arm was used. Primer sequences used are shown in Table S2. For 
southern blot, genomic DNA was extracted using the GenElute Mammalian Genomic 
DNA Miniprep Kit (Sigma G1N70-1KT). 10 µg of genomic DNA was digested 
overnight with the appropriate restriction enzyme (Table S3) and separated on a 0.8 
% agarose gel. DNA fragments were transferred by capillarity to a Hybond-N+ 
membrane (GE Healthcare RPN303B) overnight. Probes were generated by PCR 
and radioactively labeled with α-[32P] dCTP using the MegaPrime labeling kit (GE 
Healthcare RPN1604). Hybridization with the probe was carried out overnight at 
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60°C. Probes were detected using a Phosphoimager plate and the probe sequences 
are annotated in Table S3. 
 
RNA extraction and quantitative RT–qPCR 
For in vitro experiments, total RNA was extracted using TRIzol (Invitrogen) followed 
by RNA column purification using the RNA PureLink Kit (Ambion). Briefly, cells were 
scraped from cell culture dishes and homogenized by pipetting in TRIzol solution. 
After phase separation with chloroform, the RNA from the aqueous phase was 
purified with the RNA PureLink Kit and quantified by Nanodrop spectrophotometer. 
cDNA was produced with the High-Capacity cDNA Reverse transcription Kit (Applied 
Biosystems) following the manufacturer’s instructions. 
To analyze gene expression changes RT-qPCR was performed using 5 ng of cDNA 
per each real-time qPCR well. Real-time qPCRs were performed with TaqMan 
assays (Applied Biosystems) and TaqMan Universal PCR Master Mix in triplicates 
following manufacturer’s instructions (Applied Biosystems 4369016). Gene 
expression levels were normalized using the endogenous control PPIA and B2M for 
each sample and differences in target gene expression were determined using SDS 
2.4 or StepOne 2.2 plus software. Error bars represent standard deviation of samples 
performed in triplicate. The following TaqMan assays were used: EGFP 
(Mr04097229_mr), Tomato-BGHPA (custom made probe; F: 
GGGCATGGCACCGGCAGCACC, R:  CCTACTTGTACAGCTCGTCCATGCC), 
LGR5 (Hs_00173664_m1), ASCL2 (Hs_00270888_S1), SMOC2 (Hs0159663_m1), 
MUC2 (Hs_03005094_m1), KRT20 (Hs_00300643_m1), POLR1A 
(Hs00209909_m1), POLR1B (Hs00219263_m1), POLR1C (Hs01561269_g1), RRN3 
(TIF1A) (Hs_04398176_m1), pre-5’ETS-rRNA (custom), Ascl2 (Mm_01268891_g1), 
Lgr5 (Mm_0043889_m1), Muc2 (Mm_01276696_m1), Smoc2 (Mm_00491553_m1), 
and Krt20 (Mm_00508106_m1). All real-time qPCRs were normalized to B2M 
(Hs_99999907_m1), b2m (Mm_00437762_m1), PPIA (Hs_99999904_m1), and Ppia 
(Mm02342430_g1). 
 
Protein extraction and western blot analysis 
Cells were washed twice with cold PBS and scraped with lysis buffer 1:1:1 (1 mM 
EDTA, 1 mM EGTA, 1% SDS) supplemented with protease and phosphatase 
inhibitors (Sigma Aldrich) and heated at 99ºC for 10 min. Cell lysates were pipetted 
several times to break up gDNA and later centrifuged at 13200 rpm at 4ºC for 15 min. 
The supernatant was kept as the protein extract. Protein content was quantified with 
the Protein Assay (BioRad) based on the Bradford method. Equal amounts of protein 
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per sample were separated by standard SDS-PAGE and transferred to PVDF 
membranes (Millipore). The membranes were incubated in TBS-T (20mM Tris, 
150mMNaCl, 0.2% Tween 20) supplemented with 5% milk for 30 min at RT to block 
unspecific antibody binding. Primary antibodies RPA194 (POLR1A) (Santa Cruz, SC-
48385) 1:500, RRN3 (Sigma HPA049837) 1:500, KRT20 (DAKO M701929-2) 1:500, 
Actin (Abcam ab20272), 1:15000 were incubated overnight at 4ºC. Secondary 
antibodies were diluted 1:10000 and incubated for 1h at RT with the PVDF 
membranes. Membranes were washed 3 times with TBS-T 0.2% for 10 min, 
incubated for 5 min with SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific, 34080), and visualized using Odyssey Fc Imaging system (Li-
COR). 
 
In vitro click chemistry, in-gel fluorescence, IP 
Cells were lysed with 2% SDS, extracts were quantified and diluted to 1% SDS, and 
100 µg of protein was subjected to click reaction using Click-it Kit (Thermo Fisher) 
and IRDye 800CW Azide Infrared Dye (Li-COR). Samples were incubated in dark at 
room temperature for 1.5 h, and subsequently, the proteins were precipitated using 
standard methanol/chloroform protocol. Pellets were air dried and re-suspended in 
1% SDS. 20 µg of protein was boiled with sample buffer and loaded onto SDS-PAGE 
gel for further analysis of the inputs or was incubated with antibody against KRT20 
(Atlas antibodies, HPA024309) overnight at 4°C with shaking. The next day, protein 
A beads were added, and samples were incubated 1 h more under the same 
conditions. Subsequently, after extensive washes, samples were boiled with sample 
buffer and loaded onto SDS-PAGE gel followed by standard WB protocol. In order to 
detect KRT20, membranes were incubated for 1 h in dark at room temperature with 
1:5000 Goat anti-Rabbit Alexa Fluor 680 (Thermo Fisher). Membranes were washed 
3 times with TBS-T 0.2% for 10 min, incubated for 5 min with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific, 34080), and visualized using 
Odyssey Fc Imaging system (Li-COR). 
 
Analysis of protein and RNA synthesis by flow cytometry and microscopy 
To measure protein synthesis in vivo mice were injected intraperitoneally with either 
1 mg of OP-P (O-propargyl-puromycin) (Medchem Source LLP, JA-1024) or 2 mg of 
HPG (L Homopropargylglycine) (Click Chemistry Tools, 1067-100) per animal two 
hours before sacrifice. To measure RNA synthesis in vivo mice were injected i.p. with 
4 mg EU (5-Ethynyl Uridine) (Click Chemistry Tools, 1261-100) per animal two hours 
before sacrifice. Subcutaneous xenografts were collected and further processed for 
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histology or flow cytometry analysis following the standard protocols.  FACS Aria 
Fusion flow cytometer (Beckton Dickinson) was used and data were analyzed using 
FlowJo software. Using a Click-It kit (Thermo Fisher, C10457, C10428, C10329) OP-
P, HPG or EU were conjugated to a fluorochrome in tissue sections prior to antibody 
staining or in FACS sorted cells which were fixed in PFA 4% for 15 min at RT before 
Click-It reaction. Samples were then analyzed by microscopy or flow cytometry in 
each case.  Samples from non-injected mice were used to determine the background 
signal. In order to measure protein or RNA synthesis in vitro, either OP-P (20 µM), 
HPG (50 µM) or EU (1 mM) was added to the medium. Cells were incubated for 2h, 
then trypsinized to single cell state for flow cytometry analysis, fixed, and labeled by 
standard Click-It reaction protocol. For microscopy analysis, cells or organoids were 
washed two times with PBS after the incubation period, fixed and subjected to Click-
It reaction under the same conditions as stated before. When indicated, samples 
were stained with antibodies and further processed following standard 
immunofluorescence protocol. 
 
Xenografts disaggregation and cell isolation 
Xenografts were resected and disaggregated as previously described in (Merlos-
Suárez et al., 2011),(Cortina et al., 2017). Human epithelial cells from disaggregated 
PDX were first incubated 30 min at 4ºC with 1:200 CD16/CD32 (mouse, Tonbo 
Biosciences, 70-0161-U500) to block free antibody binding sites and with 1:200 
BV421-CD31 (rat, BD Biosciences, 562939cloneMEC13.3) and 1:200 BV421-
CD45RB (rat, BD Biosciences, 562849clone16A) to stain for immune and endothelial 
mouse cells. After this period, 1:150 EPCAM-PeCy7 (human, eBioScience 25- 9326-
42) or 1:100 EPCAM-APC-Vio770 (human, Miltenyl Biotec 130-101-161) was added 
and incubated for 1 h at 4ºC. Mouse tumor cells from AKP xenografts were stained 
with 1:300 EPCAM-APC-Cy7 (mouse, Biolegends, 118217 cloneG8.8). DAPI (1 
µg/ml) was added to distinguish live/dead cells. The cell suspension was analyzed 
with a BD Fusion FACS or Aria FACS. 
 
Generation of POLR1A and LGR5 signatures 
The POLR1A and LGR5 gene signatures used for the single cell RNA-seq analysis 
were generated by FACS purification of high and low or negative fluorescent tumor 
cells from subcutaneously injected POL-iCT or LGR5-iCT knock-in PDO7. The 
LGR5 signature included bonafide ISC genes that were corregulated 
with LGR5 according to the scRNAseq data. All gene signatures used in this study 




RNA from 2000 cells from each condition was extracted and retrotranscribed to 
cDNA as described in (Gonzalez-Roca et al., 2010). The cDNA was amplified for and 
purified using PureLink Quick PCR Purification Kit (Invitrogen). Quantification of 
amplified cDNA was done on a Nanodrop ND-1000 spectrophotometer 
(Thermo-Fisher Scientific, Waltham, MA, USA). 8 ug of the cDNA from 
each sample were fragmented and labeling with GeneChip Mapping 250 K 
Nsp assay kit (Affymetrix) following the instructions of the manufacturer. 
Finally, hybridization was performed using the GeneChip Hybridization, 
Wash and Stain Kit (Affymetrix). Samples ready to hybridize were denatured at 99°C 
for 2 min prior to incubation into the GeneChip Human 
PrimeView arrays (Affymetrix). Hybridization was performed for 16 h at 45°C / 60 rpm 
in the GeneChip Hybridization Oven 645 (Affymetrix). Washing 
and Stain steps after hybridization were performed in the GeneChip 
Fluidics Station 450 (Affymetrix), following the specific script for 
PrimeView arrays. Finally, the arrays were scanned with GeneChip Scanner 
GCS3000 (Affymetrix) using default parameters, and the generation of Cel 
files for bioinformatics analysis was done with Command Console 
software (Affymetrix). 
 
Cell sorting and libraries preparation for Single-cell RNA-seq 
PDO7 was infected with a CMV-CherryLuc lentiviral vector. Positively infected cells 
were sorted, expanded for two passages, and injected subcutaneously in a Beige 
nude mouse (200.000 cells in small organoid format per flank in 100µl BME2-HBSS). 
When PDX were at a mean 100m3 volume the animal was sacrificed and xenografts 
were disaggregated as described before. Cherry positive alive cells from two 
xenograft biological replicates were sorted in single cell format in 96-well plate with 
Smart-seq2 lysis buffer and frozen prior to their sequencing. For PDO-p18 2 million 
cells were injected subcutaneously. 100m3 xenografts were extracted from the NSG 
injected animal after its sacrifice, disaggregated and stained for 1h on ice with 
hEpcam-APC-770 antibody (human, Milteny Biotec, 130-101-161) at 1:150 dilution 
after 30 min of mouse antigen blocking stain with 1:100 mCD16/CD32 (Tonbo 
Biociences, 70-0161-U500), 1:100 mCD31-vio450 (BD biosciences, 
562939cloneMEC13.3) and 1:100 mCD45-vio450 (BD biosciences, 
562849clone16A). Epcam positive human cells from two different replica xenografts 
were sorted in single cell format 96MW plates with Smart-seq lysis buffer.  
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Full-length single-cell RNA sequencing libraries were prepared using the Smart-seq2 
protocol (Picelli et al.) with minor modifications. Briefly, 96-well plates containing 
sorted cells in lysis buffer were reverse transcribed using SuperScrpit II (Invitrogen) 
in the presence of oligo-dT30VN, template-switching oligonucleotides and betaine. 
The cDNA was amplified using the KAPA HiFi Hotstart ReadyMix (Kappa 
Biosystems), ISPCR primer and 22 cycles of amplification. Following purification with 
Agencourt Ampure XP beads (Beckmann Coulter), product size distribution and 
quantity were assessed on a Bioanalyzer using a High Sensitivity DNA Kit (Agilent 
Technologies). 140 pg of the amplified cDNA was fragmented using Nextera® XT 
(Illumina) and amplified with indexed Nextera® PCR primers. Products were purified 
twice with Agencourt Ampure XP beads and quantified again using a Bioanalyzer 
High Sensitivity DNA Kit. Sequencing of Nextera® libraries from 384 cells was 
carried out in one lane on an Illumina HiSeq2500 v4.  
QUANTIFICATION and STATISTICAL ANALYSES 
General quantifications 
For the ribosomal content/KRT20 ratio quantification in primary patient samples, 
scanned images were processed for quantification using Qupath software 
(https://qupath.github.io/). The epithelial area was selected and fragmented into 100 
µm2 tiles. Mean intensity for the red and green channel was measured for each tile, 
and the values were represented using a scatter plot. Consecutive slides for 8 
representative samples were stained for EPHB2 and 5.8S as a control. Densities of 
absolute-valued Log2 ratios were used to perform statistical analysis. 
For quantifying the number of KRT20 and tdTomato positive cells for the KRT20 
lineage tracing experiment, images were processed using Qupath as described 
above and the Cell detection algorithm from the same software was used. Nuclei 
were detected by using the DAPI channel with default nuclei parameters and 
tdTomato in the 568 channel. The mean intensity of KRT20 staining was measured 
for each tdTomato positive detected cell. 
For Ki67 quantification images were processed for quantification using Qupath. In 
order to compare the amount of KI67 positive cells in tumor center compared to 
tumor periphery, we selected 4 areas within each image: a center, and three zones 
representing inner (P3), outer (P2), and the outermost periphery (P1). Epithelial 
tumor cells were classified as positive or negative based on mean DAB nuclear 
intensity, and percentage of positive tumor cells within each zone was represented. 
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ImageJ was used for the quantification of the whole silde images of tissue sections 
stained for KRT20 or alcian blue. For KRT20 quantification, epithelial tumor cells 
were first selected as EPCAM+ and then we quantified the KRT20+ area within the 
epithelial compartment. Percentage of Alcian blue area represents a ratio between 
Alcian blue+ area and the total area of the tumor. 
The quantification of the nuclear area occupied by POLR1A signal was done with 
ImageJ using a Macro developed by the microscopy facility at IRB.  
 
Clonal quantification for in vivo lineage tracing  
We tested several tamoxifen doses and assessed the % of recombination by flow 
cytometry in dissociated xenograft. A tamoxifen dose of 250mg/Kg in LGR5-creERT2 
PDOs, 10mg/Kg in PORLR1A-creERT2 and 1mg/Kg in KRT20-creERT2 trigger 
recombination in 1-2% of the tdTomato+ cells in the viable epithelial fraction. We 
corroborated this result by histology. Mice were inoculated subcutaneously with 
200.000 PDO cells and treated with the indicated doses of tamoxifen when 
xenografts reached 50-70 mm3 (approximately 3 weeks after inoculation). Tumors 
were processed for histology at indicated time points.  A minimum of 4 tumor 
xenografts per cre line were analyzed. Tumors were open in half and oriented so that 
sections corresponded to the central area of the tumor. When all samples were 
collected, we performed immunohistochemical staining of 3 µm histological sections 
as described above using the primary antibody against tdTomato (rabbit, Rockland, 
600-401-379). Images for clone quantification were acquired using a NanoZoomer-
2.0 as described above. All brightfield images were visualized with a gamma 
correction set at 1.8 with the NDP.view 2U123888-01 software (Hamamatsu). For 
clonal quantification images were processed using ImageJ. Tomato positive objects 
were detected and thresholds were calculated automatically using RenyiEntropy 
function. The algorithm group objects that reside in close proximity (<13 pixels) so 
that they are considered as unique clones. Total and large clones number were 
relativized to the area (pixels) of the tumor section. To calculate number of cells, we 
estimated the size of single cells in histological sections and interpolated the number 
of cells per each clone and per section. The non-necrotic area include all tumor cells 
(epithelium and stroma) that were not necrotic and was obtained by manually training 
a machine learning tile classifier using QuPath software. This area was then divided 






POLR1A expression analysis in colon samples from human cohort 
GSE4407 dataset (Sanz-Pamplona et al., 2014) was downloaded from the NCBI 
GEO repository. These data include gene expression and clinical information from 50 
healthy human colon mucosa along with 98 tumor CRC stage II samples and their 
paired adjacent morphologically normal mucosa.  Raw cel files were normalized 
using procedure described below (see section Microarray analyses). Technical 
information concerning samples processing and hybridization was retrieved from the 
original CEL files: date of scanning were collected in order to define scan batches in 
each dataset separately; technical metrics described by Eklund AC and Szallasi Z in 
(Eklund and Szallasi, 2008) were computed and recorded as additional features for 
each sample. Expression data were corrected by metrics PM.IQR, RMA.IQR and 
RNA.DEG (Eklund and Szallasi, 2008) and by scanning day. For doing so, a linear 
model was fitted separately for each probeset that included these metrics as the only 
explanatory variables, and the coefficients of such models were used to correct the 
expression values a-priori. Next, the same procedure was carried out for correcting 
by technical effects captured by scanning date. Finally, expression intensities were 
summarized at the gene level (entrez) by the first principal component of the 
probesets mapping to the same gene. This component was centered and scaled to 
the weighted mean of the probesets’ means and standard deviations, where the 
contributions to this first component were used as weights. The sign of this score 
was then corrected sot that it was congruent to the sign of the probeset contributing 
the most to the first component.  Association between POL1RA expression and 
sample type was evaluated using a linear model (Wald test). The threshold for 
statistical significance was set at 5%. All analyses were carried out using R and 
Bioconductor (Gentleman et al., 2004). 
 
Microarray analyses 
Samples were hybridized in PrimeView Human Gene Expression Array and 
processed with packages affy (Gautier et al., 2004) and affyPLM (Bolstad et al., 
2005) from R and Bioconductor (Gentleman et al., 2004). Raw cel files were 
normalized using RMA background correction and summarization (Irizarry et al., 
2003). Probeset annotation was performed using the information available on the 
Affymetrix – Thermofisher web page (https://www.thermofisher.com/es/en/home/life-
science/microarray-analysis/affymetrix.htm. Accessed on 29/10/2019). Standard 
quality controls were performed in order to identify abnormal samples regarding: a) 
spatial artifacts in the hybridization process (scan images and pseudo-images from 
probe level models); b) intensity dependences of differences between chips (MvA 
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plots); c) RNA quality (RNA digest plot); d) global intensity levels (boxplot of perfect 
match log-intensity distributions before and after normalization and RLE plots); e) 
anomalous intensity profile compared to the rest of the samples (NUSE plots, 
Principal Component Analyses); f) impact of quality metrics (Eklund and Szallasi, 
2008) on expression measures. Samples from batch “cm.1509” in the tumor dataset 
(refers to the Ephb2 populations, Figure 1) were a priori corrected gene-wise by 
RMA.IQR metric (Eklund and Szallasi, 2008) using a linear model with no more 
covariates included in it. No samples were excluded from the study due to quality 
issues. Differential expression analysis was performed using a linear model with 
empirical shrinkage (Smyth, 2004) as implemented in the limma R package (Ritchie 
et al., 2015). Comparisons were controlled for biological replicate by including the 
sample’s donors in the model as covariates. In the tumor dataset (refers to the 
Ephb2 populations, Figure1), the models additionally included the tissue as covariate 
(Normal/Tumor) as well as the interaction between tissue and Ephb2 status. 
Benjamini and Hochberg False Discovery Rate (FDR) (Smyth, 2004)  was used for 
multiple comparisons correction. Pathway enrichment analyses were performed 
using a modification of ROAST (Wu et al., 2010), a rotation-based approach 
implemented in the R package limma (Ritchie et al., 2015) that is specially suitable 
for small size experiments. Such modifications were implemented to accommodate 
the re-standardized maxmean statistic proposed in the ROAST algorithm, in order to 
enable it for competitive testing (Goeman and Bühlmann, 2007). For visualization 
purposes, we represented these results using the Enrichment Score graphic from the 
Gene Set Enrichment Analysis (GSEA) algorithm (Subramanian et al., 2005). 
Genesets derived from the KEGG pathway database (Kanehisa and Goto, 2000) and 
the Gene Ontology (GO) (Ashburner et al., 2000) as collected in the R package 
org.Hs.eg.db were used for these analyses, as well as the Broad Hallmark gene set 
collection from the MsigDB (Liberzon et al., 2015). 
 
RNA-Seq data  
Reads were aligned to the primary assembly of the mm10 Ensembl genome 
(GRCm38) using STAR (version 2.7.0a, default parameters) (Dobin et al., 2013). 
Quantification of count per genomic feature was performed using the R package 
Rsubread (Liao et al., 2013) (function featureCounts, default parameters). GO 
(Ashburner et al., 2000)  terms were retrieved from R package org.Mm.eg.db , while 
Broad Hallmark sets were translated to mouse homologous genes using the R 
package biomaRt (Durinck et al., 2009). Expression counts were rlog-transformed 
(Love et al., 2014) and summarized at the gene set levels as follows: rlog-values 
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were centered and scaled gene-wise to produce z-scores, which were then averaged 
across all genes included in a given gene set; the resulting score were in turn 
centered and scaled across samples that were included in the dataset. Expression 
data at the gene set level were graphically represented in a heatmap using a blue to 
red color gradation, where red indicated the highest expression and white 
corresponded to the lowest expression values. For clarity, the most extreme values 
were truncated to -1.5 and 1.5. 
 
Single-cell RNA-seq data analysis 
Sequencing was carried out as paired-end (PE75) reads with library indexes 
corresponding to cell barcodes. After sequencing, libraries were inspected with the 
FastQC suite to assess the quality of the reads. Reads were then demultiplexed 
according to the cell barcodes and mapped on the human reference genome 
(Gencode release 27, assembly GRCh38 p10) with the RNA pipeline of the 
GEMTools (Marco-sola et al., 2012) 1.7.0 suite using default parameters (6% of 
mismatches, minimum of 80% matched bases, and minimum quality threshold of > 
26). 
For both PDO7 and PDO-p18, cells with <65% of mapped reads or <100,000 of total 
mapped reads were discarded. Cells with >100 genes and <25% of mitochondrial 
gene counts were included in downstream analyses, resulting in read count matrices 
containing 511 (PD07) and 388 (PD18) single cells. Genes that were expressed in 
fewer than five cells were removed. Filtering, normalization, selection of highly 
variable genes (HVG) and clustering of cells were performed according to the Seurat 
(Satija et al., 2015) package (version 2.3.4). Selection of HVG was based on the 
evaluation of the relationship between gene dispersion (y.cutoff = 0.5) and the log 
mean expression (x.high.cutoff = 3), while the total number was limited to the mean 
of genes per cell. Projections of HVG onto a reduced dimensional space was used 
for the graph-based clustering to group cells into subpopulations. At this step, the 
dimension of the subspace was set to the number of significant principal components 
(PC); based on the distribution of the PC standard deviations. The number of clusters 
was aligned to the expected biological variability and cluster identities were assigned 
using previously described gene markers and transcriptional signatures derived from 
bulk RNA sequencing of the principal cell populations. T-SNE was used to visualize 
the clustering distribution of cells. Trajectory analysis and pseudo-ordering of cells 
were performed with the Monocle (Qiu et al., 2017) package (version 2.8.0) using the 
previously identified HVG. Cell clustering and pseudo-time were consistent between 




Single-cell RNA-Seq data – enrichment analysis 
LGR5/POL1 gene expression signatures were retrieved from the scRNA-Seq 
differential expression analyses using different thresholds for fold-change and 
statistical significance. These signatures were evaluated for pathway enrichment 
using a hypergeometric test for their intersection with gene sets in the GO 
(Ashburner et al., 2000) and Hallmarks (Liberzon et al., 2015) collections. 
 
Statistical analyses 
To test statistical significance between samples from two different groups two-tailed 
Student’s t-tests were used. When comparing samples from the same animal paired 
t-tests were applied. When comparing different groups within different variables, 
multiple comparison two-way ANOVA Tukey’s tests were used. For Figure 1G, 4K 
and 4M a mixed effects linear model was fitted with technical replicates taken as 
random effects and PDOs as fixed effects. The "lmer" function from the lme4 (Bates 
et al., 2014) R package was used for fitting the model. Coefficients and p-values for 
the comparisons of interest were computed through the "glht" function from the 
multcomp (Hothorn et al., 2008) R package using the "Westfall" multiplicity 
adjustment method. Confidence intervals for the coefficients were calculated with the 
"confint" function. Plots were generated using R programming language (Bunn, 
2014). Data from 5.8S and KRT20 staining of FFPE primary CRCs (Figure 3J and 
S3D) were represented in a smoothed scatterplot using the R function smoothScatter 
(Bunn, 2014), where the color intensity corresponded to the density of data points 
through a 2-dimension kernel estimate. Joint distribution of KRT20 and 5.8S values 
were tested against a proper set of negative control samples stained with 5.8S and 
EPHB2 (data not shown).  Log2-ratios of the corresponding marker against 5.8S 
values were computed for each stain data point. Each sample was then summarized 
by the median of the absolute value of these log2-ratios. Distributions of these values 
for KRT20 and EPHB2 samples were then compared using a Komolgorov-Smirnov 
test. For Kapplan-Meier curves, Gehan-Breslow-Wilcoxon test was applied. In growth 
kinetics experiments statistical significance was obtained by comparing the relative 
tumor volume of the last measure from control subjects with the corresponding 
measure of treated animals in a two-tailed Student’s t-test. All group data are 
represented by the mean and errors bars are the standard error of the mean (s.e.m) 





Sample sizing and collection 
All samples and animals were assigned randomly to experimental conditions, as well 
as the sample collection. Automated quantifications and blind data analysis were 
done whenever possible. A minimum of three representative images was quantified 
in each experiment and each condition.   
 
EXCEL TABLE TITLE AND LEGENDS 
 
Table S5. Gene Signatures used in this study, Related to Figure 5 and 7. 
Gene signatures (POLR1A high, POLRA low, and LGR5) used for the scRNA-seq 
analysis and (Stemness, Proliferation and Differentiation) used for the RNA-seq 
analysis of AKP organoids. 
 
Table S6. Gene Set Enrichment Analysis (GSEA), Related to Figure 1, 7 and S4. 
GO categories enriched in EPHB2 high vs low, LGR5+ vs LGR5- in POLR1A high, 
and early vs long differentiation of AKP organoids. 
 
Table S7. Gene Set Enrichment Analysis (GSEA) of scRNA-seq, Related to 
Figure 5. 
GO categories enriched in POLR1A-high vs LGR5+ (PDO7) and POLR1A-
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KEY RESOURCES TABLE  
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Goat Anti Mouse EphB2 R&D systems 
Cat# AF467 
RRID: AB_355375 
Goat Anti Human EpCAM /TROP-1 R&D systems 
Cat# AF960 
RRID: 355745 
Anti-Ki67 BD Biosciences 
Cat# 550609 
RRID: 393778 
RPA194 (C-1) antibody Santa Cruz 
Cat# sc-48385 
RRID: AB_675814 
tdTomato polyclonal antibody Sicgen 
Cat# AB8181-200 
RRID: AB_2722750 
Anti-RFP/tdTomato antibody Rockland 
Cat# 600-401-379 
RRID: AB_2209751 
GFP antibody Abcam 
Cat# ab183734 
RRID: AB_2732027 
Cytokeratin 20 antibody Dako 
Cat# M7019 
RRID: AB_2133718 
Anti-Mouse CD16 / CD32  Tonbo Biosciences 
Cat# 70-0161 
RRID: AB_2621487 
BV421 Rat Anti-Mouse CD31 Clone MEC 
13.3  
BD Biosciences 
Cat# 562939  
RRID: AB_2665476 
BV421 Mouse CD45RB Clone 16A BD Biosciences 
Cat# 562849 clone16A 
RRID: AB_2737836 











APC/Cyanine7 anti-mouse CD326 (Ep-CAM) 
antibody 
Biolegends 
Cat# 118217, RRID: 
AB_1501158 
APC anti-human EphB2 antibody (2H9 clone) BD Biosciences 





































BightVision poly-HRP anti-Rabbit Immunologic DPVR-110HRP 
Rabbit anti-RRN3 Sigma-Aldrich/Merck HPA049837 
Mouse anti-bActin Abcam 20272 
KRT20 Atlas Antibodies HPA024309 





Patient derived organoids (PDOs 




et al., 2011) 
n/a 
Mouse derived organoids (shAPC-KP) (Dow et al., 2015) n/a 
Experimental models: cell lines 
LS174T ATCC CL-188 
SW403 ATCC CCL-230 
Chemicals, Peptides, and Recombinant Proteins 






Doxycicline hyclate Sigma-Aldrich/Merck D9891 
5-Fluorouracil (5-FU) Sigma-Aldrich/Merck F6627 
Irinotecan Sigma-Aldrich/Merck I1406 
Leucovorin Sigma-Aldrich/Merck 47612 
















Matrigel growth factor reduced Corning 356231 













N-Acetyl-L-cysteine Sigma-Aldrich/Merck A7250- 
Nicotinamide Sigma-Aldrich/Merck 72340 





Noggin In house n/a 
R-spondin In house n/a 
Rock inhibitor, Y-27632 Med Chem express HY-10583   
Gastrin I Tocris 3006 
TGFb-RI inhibitor, A83-01 Tocris 2939 
P38a/b inhibitor, SB202190 
monohydrochloride hydrate 
Sigma-Aldrich/Merck S7076 
TGFb-RI inhibitor (galunisertib), LY2157299 In house n/a 





5-Ethynyl uridine (EU) Click chemistry Tools 1261-100 
O-propargyl-puromycin (OPP) Medchem Source JA-1024 
L-homopropargylglycine (HPG) Click chemistry Tools 1067-100 
Polymerase I inhibitor, BMH-21 Invivochem V1435 
Cell recovery solution Corning 354253 
Proteinase K Thermo Fisher Scientific 25530049 





Smart-seq2 lysis buffer In house 
Picelli S. et al., 2014 n/a 
Critical commercial assays  





Nucleospin Plasmid QuickPure Miniprep Kit Cultek  740615250 
PureLink® RNA Mini Kit  Thermo Fisher 
Scientific 
12183025 
GenElute Mammalian Genomic DNA 
Miniprep Kit Sigma-Aldrich/Merck G1N70-1KT 
Cell Line Nucleofector® Kit V  Cultek (Lonza) VCA-1003 








Click-iT™ Plus OPP Alexa Fluor™ 594 










GeneChip Human PrimeView array Affymetrix 901837 
GeneChip Mapping 250 K Nsp assay kit Affymetrix 900753 




High sensitivity DNA Kit Agilent Techonologies 5067-4626 
Nextera® XT DNA Library Prep Kit ® XT Illumina FC-131-1024  
MegaPrime labeling kit GE Healthcare RPN1604 
Reagent or resource 
SYBR® Green PCR Master Mix Thermo Fisher 
Scientific 
4368706 




Phusion High Fidelity DNA Polymerase  Thermo Fisher Scientific  F530L  
DNA Polymerase Biotools 10.014 
SuperScript II Reverse Transcriptase Thermo Fisher Scientific 18064022 
Agencourt Ampure XP beads Beckman coulter A63880  
KAPA HiFi Hotstart ReadyMix Roche KR0370 
Trizol Thermo Fisher Scientific 15596018 
Schiff’s Reagent  Panreac  171588.1609 
Alcian Blue solution Panreac CA254584.1604 
DPX Panreac 255254 
Peroxidase blocking solution Dako S202386 
Envision Flex antibody diluent Agilent K8006 




Normal Goat Serum  Jackson 
immunoresearch 005-000-121 
DAPI-Fluoromount-G Mounting Medium Southern Biotech 0100-20 




Oligonucleotide   
sgRNA guides This paper Table S1 
Genotyping This paper Table S2 
Southern probes This paper Table S3 
Taqman primers This paper STAR Methods 
Deposited data   
Microarrays and RNA-seq This paper GEO: GSE125232 
Single cell RNA-seq This paper GEO: GSE148345 
Software and Algorithms   
FlowJo  BD Biosciences https://flowjo.com 
NDP.view2 n/a www.hamamatsu.com 
Fiji Schindelin et al., 2012 https://imagej.net/Fiji 
GraphPad Prism Prism software RRID: SCR_002798 
Illustrator CS6 Adobe RRID: SCR_010279 
StepOne 2.2 plus and SDS2.4 Thermofisher  www.thermofisher.com 
BD FACS Diva Software BD Biosciences RRID: SCR_001456 
ScanR Software n/a www.olimpus-lifesciences.com 
Zeiss LSM 780 Software n/a www.zeiss.com 
QuPath n/a https://qupath.github.io/ 
R language and environment for statistical 
computing R core team (2019) https://cran.r-project.org/ 
affy package Gautier et al., 2004 https://bioconductor.org  
affy PLM package Bolstad et al., 2005 https://bioconductor.org  
Limma R package Ritchie et al., 2015 https://bioconductor.org  
STAR version 2.7.0a Dobin et al., 2013 https://github.com 
R package Rsubread Liao et al., 2019 https://bioconductor.org  
R package BiomaRt Durinck et al., 2009 https://bioconductor.org 
DESeq2 R package Love MI et al., 2014 https://bioconductor.org 





FastQC Suite n/a 
https://www.bioinformatic
s.babraham.ac.uk 
GEMT Tools 1.7.0. Marco-Sola et al., 2012 http://gemtools.github.io 
Seurat package 2.3.4 Satija et al., 2015 https://bioconductor.org  
Monocle package 2.8.0 Qiu et al., 2017 https://bioconductor.org  
Ime4 R package Bates et al., 2014 https://cran.r-project.org 
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Figure S1. OP-P and EU Incorporation in CRC models, Related to Figure 1. 
 
(A) OP-P incorporation and KRT20 staining in primary human CRC implanted 
orthotopically into the caecum of immunodeficient mice. (A’) and (A”) show representative 
insets of (A). Str: Stroma. Scale bars: in (A): 2.5 mm; in (A’): 250 µm; in (A”): 250 µm. 
(B) OP-P incorporation and KRT20 staining in human hepatic metastasis implanted 
orthotopically into the liver of immunodeficient mice. (B’) and (B”) show representative 
insets of (B). Str: Stroma. Scale bars: in (B): 2.5 mm; in (B’) and (B”): 100 µm. 
(C) EU incorporation and KRT20 staining in primary human CRC implanted orthotopically 
into the caecum of immunodeficient mice. (C’) and (C”) show representative insets of (C). 
Str: Stroma. Scale bars: in (C): 2.5 mm; in (C’): 100 µm and in (C”): 250 µm. 
(D) EU incorporation and KRT20 staining in liver metastasis generated from intrasplenic 
(IS) injection of PDO7. (D’) and (D”) show representative insets of (D). Str: Stroma. Scale 
bars: in (D): 2,5 mm in (D’) and (D”): 250 µm.  
(E) Experimental design for the analysis of OP-P and EU incorporation in EPHB2 tumor 
cell populations purified from PDXs. 
(F) EPHB2 and KRT20 staining (left) and OP-P incorporation (right) in a PDX. Scale bars: 









































































































elated to Figure 1
Figure S2. Proliferation is not Limited to the Tumor Periphery in CRC, Related to 
Figure 2. 
 
(A and B) Ki67 staining in surgically resected human CRC tumors implanted into the 
caecum of immunodeficient mice. (A’) and (B’) show in more detail the center of the tumor, 
and (A”) and (B”) show the periphery. Scale bars in (A) and (B): 2.5 mm; in (A’), (A”), (B’), 
and (B”): 250 µm. 
(C) Experimental design for the quantification of KI67 positive tumor cells in different areas 
of the tumor. The panel indicates selected areas for quantification: three layers of the 
periphery (P1-P3) and a central region (Center). 
(D) Quantification of Ki67 positive tumor cells in the indicated areas of 5 different 
orthotopic tumors (T2-T6). 
(E) Representative Ki67 staining in primary human CRC. (E’) shows in more detail the 
center of the tumor and (E”) shows the periphery. Scale bars in (E): 2.5 mm; in (E’) and 
(E”): 250 µm. 
(F) Quantification of Ki67 positive tumor cells in 4 different primary human CRC samples. 
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Figure S2-Related to Figure 2
Figure S3. Downregulation of rDNA Transcription and Loss of Ribosomal Content 
upon Tumor Cell Differentiation, Related to Figure 3. 
 
(A and B) EU incorporation and KRT20 expression in SW403 tumor cells (A) and in AKP 
organoids (B) upon in vitro differentiation at indicated time points. Scale bars: 50 µm.  
(C) 5.8S and KRT20 staining of 6 representative primary human CRC samples. Scale 
bars: 1mm. 
(D) Quantification of KRT20 and 5.8S (Y10B antibody) intensity of 24 analyzed primary 
human CRC tumors. For the analysis, each sample was split into 10 µm2 tiles and the 
intensity of KRT20 and 5.8S was quantified and represented in dot plots. The figure shows 
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Figure S3-Related to Figure 3
Figure S4. Characterization of POLR1A Tumor Cell Population in vitro and in vivo, 
Related to Figure 4. 
 
(A) POLR1A and KRT20 staining in control (Wnt ON) or differentiated (Wnt OFFF) CRC 
SW403 cell line. Scale bars: 20µm. Images are tiled and stitched. 
(B and C) POLR1A and KRT20 staining in tumor-derived xenografts from PDO7 (B) and 
PDO-p18 (C). White squares demark representative insets. Scale bars: 100 µm. Images 
are tiled and stitched. 
(D) POLR1A gene expression in human colon normal mucosa (n=50) compared to 
colorectal adenocarcinomas (n=98). Association between POL1RA expression and sample 
type was evaluated using a linear model (Wald test). 
(E) In vitro colocalization of POLR1A protein in red (left) and endogenous EGFP-POLR1A 
(right) in knock-in organoid PDO7. Scale bars: 20µm. 
(F) EGFP-POLR1A and KRT20 staining in tumor-derived xenografts from injected knock-in 
PDO7. Scale bars: 50 µm. 
(G) Representative flow cytometry plot of EGFP-POLR1A expression in untargeted (left) or 
in knock-in PDO7 tumor xenograft (right). Squares indicate the gating used for sorting 
EGFP-POLR1A populations. 
(H) RT-qPCR analysis of EGFP and POLR1A in sorted EGFP-POLR1A population 
indicated in (G). Bars depict the mean and the upper/lower limits of relative expression 
from a representative experiment. 
(I) Representative flow cytometry plots of EU (left) and OP-P (right) incorporation in EGFP-
POLR1A populations sorted from tumor-derived xenografts from injected knock-in PDO7. 
(J) Organoid formation efficiency of EGFP-POLR1A populations sorted from tumor-derived 
xenografts from injected knock-in PDO7 (left) and PDO-p18 (right). **p=0.0095, 
****p<0.0001 in an unpaired two-tailed t-test. Confidence intervals are mean±SEM. Right 
panels show representative images of organoid formation efficiency of POLR1A population 
in PDO-p18. Scale bar: 100 µm. 
(K) Experimental set up for the metastasis initiation capacity experiment in (L). 
(L) Quantification of liver photon flux (photons per second) after intraspleen injection of 
45.000 sorted cells of POLR1A-tdTomato high and low tumor cells purified from tumor-
derived xenografts from injected knock-in PDO7. Right panel: representative images of 
liver metastases at the end point. White arrowheads indicate metastases. 
(M) Knock-in constructs for the generation of double EGFP-POLR1A and LGR5-
iCaspase9-tdTomato (LiCT) knock-in PDO7.  
(N) Percentage of POLR1A high and low cells within LGR5+ and LGR5- tumor cell 
populations from double knock-in PDO7. 
(O) Gene set enrichment analysis (GSEA) of LGR5+ versus LGR5- within POLR1A high 
tumor cells. For all hallmarks p-val<0.05. 
(P) Gene set enrichment analysis (GSEA) of the mTORC1 (left) and Wnt signaling (right) 
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Figure S4-Related to Figure 4
Figure S5. scRNA-seq and lineage tracing analysis of POLR1A, LGR5 and KRT20 
tumor cell populations, Related to Figure 5. 
 
(A and B) Cluster-specific plots of 388 (PDO-p18)(A) and 511 (PDO7)(B) single cells from 
tumor xenograft displaying the relative expression of ISC markers (LGR5, SMOC2), 
POLR1A low signature and differentiation markers of absorptive (LAMC2), 
enteroendocrine (KRT20, NEUROG3) and mucosecreting (MUC2) lineages. 
(C and E) POLR1A high signature color-coded by the pseudo-time ordering of cells of 
PDO-p18 (C) and PDO7 (E). 
(D and F) LGR5 signature, LGR5 mRNA, POLR1A high and POLR1A low gene signature 
across the different cluster identities in PDO-p18 (D) and PDO7 (F). 
(G) Representative flow cytometry plots of tdTomato positive cells in tumor xenorafts 3 
days after tamoxifen induction in the three different populations. Right panel represents the 
average of tdTomato positive cells for the different tumors analyzed in each population 
(POLR1A: n=3, LGR5: n=4, KRT20: n=5). p>0.05 in an unpaired Tukey’s multiple 
comparison test. Confidence intervals are mean±SEM.  
(H) Average ratio of viable epithelium over time for all tumors analyzed in the tracing 
experiments for each population.  
(I) KRT20 and tdTomato staining in tumor sections 3 days after tamoxifen induction of 
KRT20 tracing. Arrowheads show single tdTomato positive cells (left) or double positive 
tdTomato/KRT20 positive cells (right). Images are tiled and stitched. 
(J) Percentage of double (tdTomato and KRT20) and single (tdTomato) positive cells at 
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Figure S5-Related to Figure 5
Figure S6. Ablation of POLR1A tumor cells induces tumor growth arrest and cell 
differentiation, Related to Figure 6. 
 
(A) RT-qPCR analysis of tdTomato and POLR1A in POLR1A-iCT (POLiCT) high and low 
populations purified from in vivo knock-in PDO7 and PDO-p18. Bars depict the mean and 
upper/lower limits of relative expression obtained from a representative experiment. 
(B) Representative images of tdTomato staining in tumor-derived xenografts from injected 
POLiCT knock-in PDO7 (left) and PDO-p18 (right) under control conditions (upper panels) 
or after 5 days of POLR1A ablation (lower panels). tdTomato is shown in rainbow. Scale 
bars:  2.5 mm, 500 µm and 1 mm.  
(C) Quantification of OPP (left panel) and EU (right panel) positive cells in POL-iCT high 
and low populations purified from in vivo knock-in PDO7. For OP-P *p=0.015 (n=2 mice) 
and for EU **p=0.0018 (n=5 mice) in a paired two-tailed t-test. Confidence intervals are 
mean±SEM. 
(D) EU incorporation in untreated tumors (control) or after 10 days of POLR1A tumor cell 
ablation (dimerizer) in PDO7 and PDO-p18. Scale bars: 250 µm. 
(E) Representative images of PAS and Alcian blue staining in control or after 10 days of 
POLR1A ablation in PDO7. Scale bars: 2.5mm  
(F) Quantification of Alcian blue positive area. For PDO7: ***p=0.0004 (Controls n=8 and 
Dimerizer n=7 tumors). For PDO-p18: p=0.054 (Control n=4 and Dimerizer n=5 tumors) in 
an unpaired two-tailed t-test.  Confidence intervals are mean±SEM. 
(G and H) Representative images showing the efficiency of LGR5 ablation in PDO7 
knocked-in with LiCG (G) or PDO-p18 knocked-in with LiCT (H). Scale bars: 2.5 mm. 
(I) Experimental design of the chemotherapy treatment. 
(J) Absolute tumor growth during chemotherapy treatment (Folfiri) in PDO-p18 (left panel) 
and PDO7 (right panel). Animals bearing subcutaneous xenografts were injected 
intraperitoneally with a single dose of Folfiri at indicated time points. At endpoints for PDO-
p18 ***p=0.0002 (Controls n=4 and Folfiri n= 8 tumors). For PDO7 ****p<0.0001 (Controls 
n=7 and Folfiri n=8 tumors) in an unpaired two-tailed t-test. Confidence intervals are 
mean±SEM. 
(K) Representative flow cytometry plots showing tdTomato expression in knock-in POLiCT 
PDO-p18 (upper panel) and PDO7 (lower panel) at the end of chemotherapy treatment. 
Dashed line represents unlabelled parental tumors (WT). 
(L) OPP incorporation and KRT20 expression in PDO-p18 untreated tumors or after 10 
days of Folfiri treatment. Scale bars: 250 µm. Images are tiled and stitched. 
(M) Quantification of the relative KRT20 area in control and Folfiri treated tumors at end 
point in (J). For PDO7: *p=0.01 (Controls n=6 and Folfiri n=9 tumors). For PDO-p18: 
***p=0.0002 (Controls n=7 and Folfiri n=7 tumors) in an unpaired two-tailed t-test.  
Confidence intervals are mean±SEM. 
(N) Western blot analysis of POLR1A, KRT20 and SDCBP2 levels in PDO7 upon 24h of in 
vitro BMH-21(1µM) treatment.  
(O) RT-qPCR analysis of ISC and differentiation genes in PDO7 after 24h of in vitro BMH-
21(1µM) treatment. Bars depict the mean and upper/lower limits of relative expression 
obtained from a representative experiment. 
(P) KRT20 staining of PDO7 organoids after 24h of in vitro BMH-21 treatment. Scale bars: 
100µm. Images are tiled and stitched. 
(Q) Absolute tumor growth during BMH-21 treatment. Animals bearing subcutaneous 
xenografts were injected intaperitoneally daily with 100 mg/Kg of BMH-21. At end points 
*p=0.026 (Control=8 and BMH21=8 tumors) in an unpaired two-tailed t-test. Confidence 
intervals are mean±SEM. 
(R) Quantification of relative KRT20 area in control and BMH-21 treated tumors at the end 
point in (Q). p=0.06 (Controls n=8 and BMH21 n=8 tumors) in an unpaired two-tailed t-test. 






























































































































































































































































































































































































































Figure S6-Related to Figure 6
Figure S7. Irreversible Tumor Cell Differentiation, Related to Figure 7 
 
(A) Tumors that grew under dimerizer treatment in vivo were dissociated and cells were 
plated in vitro to test the acquisition of dimerizer resistance. 
(B) Viability flow cytometry plots of control or resistant cells (dimerizer stop and dimerizer 
always) treated with dimerizer in vitro. 
(C) GFP (shAPC reporter) and KRT20 expression in AKP organoids that were 
differentiated (APC ON) during 2 or 5 days and recovered for 7 more days (APC OFF). 
Notice that after 5 days of APC ON reversion is not possible and organoids remain 
differentiated. Scale bars: 50 µm. 
(D) Experimental design of the organoid formation experiment. Representative images of 
AKP organoid formation efficiency experiments during in vitro differentiation (ON) and after 
reversion (ON/OFF). 
(E) EU was injected into animals bearing subcutaneous AKP organoids that were either 8 
or 20 days without doxycycline (APC ON) and were recovered for an additional 40 or 28 
days (APC OFF). Images show EU incorporation in control (APC OFF 48d), reverted (APC 
ON 8 or 20/OFF) and differentiated (APC ON 48d) tumors. Scale bars: 50 µm. Images are 
tiled and stitched. 
(F) Experimental design of (G). 
(G) Gene set enrichment analysis (GSEA) in AKP organoids in control (shAPC OFF) 
versus early (2 days) or late (7 days) differentiation (shAPC ON).  
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Figure S7-Related to Figure 7
	
	
Supplementary Tables 1-4 
 
Table S1. sgRNA guides, Related to STAR Methods. 
Locus-insertion sgRNA sequence 
POLR1A ATG                       CTTGGAGATCAACATCCTCC 
POLR1A 3’UTR    GAGCTGGGCAGATGGTGCCG 
LGR5 3’UTR    TGTCTCTAATTAATATGTGA 
KRT20 3’UTR    ATATCTAAATAGCTACCAGA 
AAVS1-BFPTOM    GTCCCTAGTGGCTAAGGC 
  
 
Table S2. Genotyping primers, Related to STAR Methods. 
Locus-insertion 5’ specific 3’ specific 
EGFP-POLR1A F: CTGATAACTTCTTTAGCCAAAGT R:	GCTGAACTTGTGGCCGTTTA 
F: ACATGGTCCTGCTGGAGTTC 
R: AGATGTACAGACAGCTGAACAAAT 
POLR1A-iCT F:	AAAGCTCCTGATTGATAACTTGG R:	AAGACGGCAATATGGTGGAAAAT 
F:	GCATTGTCTGAGTAGGTGTCATT 
R:	AATACATTTCCCTGGCATGGACA 





















AAVS1-BFP-TOM F: GGACCACTTTGAGCTCTACTGG R: GGGCCATTTACCGTAAGTTATGTA 
F: GCATTGTCTGAGTAGGTGTCATTC 
R: ATGAGATGGTGGACGAGGAAGG 
   
 





Reporter Primer Restriction enzyme 
EGFP F: CCACCATGGTGAGCAAGGGCGAGG R: TTACTTGTACAGCTCGTCCATGCC BglII 
TdTOMATO F: GGGCATGGCACCGGCAGCACC R: CCTACTTGTACAGCTCGTCCATGCC KpnI 
	
	
Table S4. PDO genotypes, Related to Figures 1-6 
 






















WT WT WT WT (insensitive to Nutlin-3a)* 






PDOX1 APC p.D1483fs KRAS p.A146V n.d. n.d. TP53 p.R282W 
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